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ABSTRACT
Engineering of polyketide biosynthetic pathways for bioactive molecules
by
Siyuan Wang, Doctor of Philosophy
Utah State University, 2016

Major Professor: Jixun Zhan
Department: Biological Engineering

Polyketides are a large group of structurally diverse natural products that have
shown a variety of biological activities. These molecules are synthesized by polyketide
synthases (PKSs). PKSs are classified into three types based on their sequence, primary
structure, and catalytic mechanism. Because of the bioactivities of polyketide natural
products, this study is focused on the engineering of PKS pathways for efficient
production of useful bioactive molecules or structural modification to create new
molecules for drug development.

One goal of this research is to create an efficient method to produce
pharmaceutically important molecules. Seven biosynthetic genes from plants and
bacteria were used to establish a variety of complete biosynthetic pathways in
Escherichia coli to make valuable plant natural products, including four
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phenylpropanoid acids, three bioactive natural stilbenoids, and three natural
curcuminoids. A curcumin analog dicafferolmethane was synthesized by removing a
methyltransferase from the curcumin biosynthetic pathway. Furthermore, introduction
of a fungal flavin-dependent halogenase into the resveratrol biosynthetic pathway
yielded a novel chlorinated molecule 2-chloro-resveratrol. This demonstrated that
biosynthetic enzymes from different sources can be recombined like legos to make
various plant natural products, which is more efficient (2-3 days) than traditional
extraction from plants (months to years). Phenylalanine ammonia-lyase (PAL) is a key
enzyme involved in the first biosynthetic step of some plant phenylpropanoids. Based
on the biosynthetic pathway of curcuminoids, a novel and efficient visible reporter
assay was established for screening of phenylalanine ammonia-lyase (PAL) efficiency
in Escherichia coli.

The other goal of this research is to characterize and engineer natural product
biosynthetic pathways for new bioactive molecules. The biosynthetic gene cluster of
the antibacterial compound dutomycin was discovered from Streptomyces minoensis
NRRL B-5482 through genome sequencing. Confirmation of the involvement of this
gene cluster in dutomycin biosynthesis and creation of a series of new molecules were
successfully conducted by rationally modifying the biosynthetic pathway. More
importantly, a new demethylated analog of dutomycin was found to have much higher
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antibacterial activity against Staphylococcus aureus and methicillin-resistant
Staphylococcus aureus.
(174 pages)
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PUBLIC ABSTRACT
Engineering of polyketide biosynthetic pathways for bioactive molecules
by
Siyuan Wang, Doctor of Philosophy
Utah State University, 2016

Major Professor: Jixun Zhan
Department: Biological Engineering

This study is focused on engineering of natural product biosynthetic pathways for
efficient production of pharmaceutically important molecules or generation of new
bioactive molecules for drug development.

Plant natural products are an important source of therapeutics, such as paclitaxel
(anticancer) and artemisinin (anti-malarial). Production of plant natural products relies
on conventional plant cultivation and solvent extraction, which is time-consuming and
cost-ineffective. This work built a biosynthetic platform in Escherichia coli using
seven biosynthetic genes from plants and bacteria, which were used to make valuable
compounds such as the strong antioxidant resveratrol and anti-inflammatory agent
curcuminoids. Through different combinations of these genes, E. coli was engineered
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to produce four phenylpropanoid acids (cinnamic acid, p-coumaric acid, caffeic acid,
and ferulic acid), three bioactive natural stilbenoids (resveratrol, piceatannol and
pinosylvin), and three natural curcuminoids (curcumin, bisdemethoxycurcumin and
dicinnamoylmethane). “Unnatural” natural products including dicafferolmethane and
2-chloro-resveratrol were also generated by modifying the existing pathways. Based
on the color of curcuminoids, a novel and efficient visible reporter assay was
established for screening of phenylalanine ammonia-lyase (PAL), an enzyme involved
in the first biosynthetic step of many plant natural products.

Actinomycetes are a group of bacteria well-known for the production of
antibiotics. A strong antibacterial agent, dutomycin, was discovered from
Streptomyces minoensis NRRL B-5482. Through genome sequencing and targeted
gene disruption, a type II polyketide biosynthetic gene cluster was found to be
responsible for the assembly of dutomycin. Several key enzymes in the pathway were
functionally characterized and a series of new analogs were generated, including a
new compound with more promising antibacterial activity.

Metabolic engineering of natural product biosynthetic pathways showed its
promise for creating and producing valuable compounds with chemical diversity for
drug discovery. This research has biosynthesized 17 valuable molecules with
medicinally relevant bioactivities. The results from this study provided important
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platforms and technical basis for further engineering polyketide biosynthetic pathways
to produce valuable bioactive molecules and generate novel analogs for bioactivity
screening and drug development.
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CHAPTER 1 INTRODUCTION

1.1 Background
Polyketides are a class of secondary metabolites produced by bacteria, fungi, and
plants, such as rapamycin, erythromycin, and lovastatin. They draw more and more
attention from scientists and engineers in the biomedical field due to their biological
activities, potential for drug discovery, and commercial value. These natural products
have displayed a variety of biological activities, such as antibacterial, anticancer,
antifungal,

antiparasitic,

coccidiostats,

and

immunosuppressive

properties.

Engineering of polyketide biosynthetic pathways allows the generation of novel
compounds that are difficult to be synthesized by other methods. Type I PKSs are
multifunctional enzymes that are arranged into modules with different catalytic
domains. Ketosynthase (KS), acyl transferase (AT), and acyl carrier protein (ACP) are
the essential domains for polyketide chain elongation. Other functional domains like
ketoreductase (KR), enoyl reductase (ER), dehydratase (DH), and methyltransferase
(MT) may be involved according to different polyketide structures. Type I PKSs are
found in bacteria, fungi, and other organisms.

Type II PKSs are aggregates of small discrete proteins with different
mono-functions. This group of PKSs is essentially involved in the biosynthesis of
bacterial aromatic polyketides [1], such as oxytetracycline [2] and pradimicin [3-5].
The minimal PKS of type II PKSs is composed of KSα, KSβ (chain length factor, CLF)
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and ACP. The nascent polyketide chain synthesized by the minimal PKS is subjected
to further modifications by KR, cyclase (CYC), methyltransferase (MT) and
glycosyltransferase (GT). The polyketide backbone is generated by condensation of
an acyl starter unit and multiple malonyl-CoA extender units. In addition to
malonyl-CoA that is a common starter and extender unit, other CoA substrates such as
fatty acyl-CoAs and benzoyl-CoA also act as starter units in aromatic polyketide
biosynthesis [1-5]. This feature enables the structural diversity and unique biological
activities of aromatic polyketides. Based on the polyphenolic ring system and their
biosynthetic pathways, bacterial aromatic polyketides can be classified into different
subfamilies, such as anthracyclines, angucyclines, aureolic acids, tetracyclines,
tetracenomycins, pradimicin-type polyphenols, and benzoisochromanequinones [6].

Anthracyclines are ranked among the most effective anticancer drugs that have
been developed [7]. The first two anthracyclines discovered were named rhodomycin
and cinerubicin [8]. A few years later, daunorubicin (trade name Daunomycin) was
isolated from Streptomyces peucetius in the 1950s by Farmitalia Research
Laboratories as well [9]. Anthracyclines inhibit DNA and RNA synthesis and
topoisomerase II enzyme to prevent the rapidly growth of cells [10-12]. Also, they
can generate free oxygen radicals to damage the DNA, protein and cell membranes
[10]. Hence, several anthracyclines, including daunorubicin, epirubicin, doxorubicin
and aclacinomycin, are used in clinic for cancer chemotherapy. The main producer of
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anthracycline polyketides in the nature is streptomycetes, which are well-known
producers of structurally and functionally diverse molecules [13,14].

Dutomycin (Fig. 1) is an anthracycline that was first isolated from soil bacteria
Streptomyces sp. 1725 from a soil sample collected in Yunnan, China [15]. This
compound showed strong in vitro cytotoxic activity against leukemia P388 [15].
Dutomycin consists of a tetracyclic anthraquinone core structure and associated sugar
moieties, which is similar to other anthracycline antibiotics such as polyketomycin,
daunorubicin, epirubicin, doxorubicin and aclacinomycin. All of these compounds are
generated by the corresponding producers through a type II polyketide biosynthetic
pathway [16]. Dutomycin is structurally similar to polyketomycin from Streptomyces
sp. MK277-AF1, which showed activity against Gram-positive bacteria including the
multi-drug-resistant strain methicillin-resistant Staphylococcus aureus (MRSA) [17].

H3C
O

CH3

O
CH3

O
CH3

CH3
O

OH

O
O

CH 3
OH

O

H3CO

OH

O
OH
O

OH

O

O

CH3

Fig. 1 The structure of dutomycin.

Type III PKSs are single enzymes can conduct substrate priming, polyketide
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chain extension, and cyclization to form polyketide products. They are small dimeric
proteins (40-45 kDa) that catalyze iterative condensation reactions with malonyl-CoA.
In recent years, type III PKSs, especially plant type III PKSs, drew more and more
attentions since their applications in medicine and agriculture. Plant type III PKSs
have been extensively studied since the first type III PKS was discovered in the 1970s
[18]. The major compounds produced by plant type III PKSs are flavonoids,
stilbenoids and curcuminoids.

Stilbenoids (Fig. 2), containing a C6-C2-C6 structure, are a class of plant
secondary metabolites which are often involved in injury control when the plant is
threatened by bacteria or fungi [19]. These molecules have shown a variety of
biological properties, such as antioxidant, antibacterial [20], antifungal [21],
anticancer, anti-inflammatory [22] and anti-aging activities [23]. Their biosynthesis
has been studied in plants [24], yeast and mammal cells [25]. Stilbene synthase (STS)
is a type III PKS that plays an essential role in the biosynthesis of stilbenoids. In 2003,
Becker J. et al. first reported the reconstruction of a biosynthetic pathway consisting
of 4-coumaroyl coenzyme A ligase (4CL) and STS in S. cerevisiae to produce
resveratrol [26]. When 5 mM p-courmaric acid was supplemented, resveratrol was
produced by engineered strains of S. cerevisiae and E. coli at 6 mg/l and 16 mg/l,
respectively [27]. Also, Watts

et al. reconstituted the same biosynthetic pathway

work in E. coli with a titer of >100 mg/l [28]. Further improvements were made since
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then. For instance, Zhang et al. used a fusion protein of 4CL and STS to increase the
yield of resveratrol in S. cerevisiae by about 20 folds [25]. Coincidentally, Lim et al.
finally improved the titer to 2.3 g/l resveratrol with this precursor pathway by testing
different STS genes from various plant species and optimizing the expression
platform in E. coli [29].
OH

OH

HO

HO

HO
OH

OH

OH

Resveratrol

OH

Pinsoylin

Piceatannol

Fig. 2 Structures of three major natural stilbenoids.
Stilbenoid biosynthesis uses cinnamoyl-CoA or p-coumaroyl-CoA as the starter
unit, meaning that it shares the early biosynthetic steps as in the biosynthesis of
flavonoids and isoflavonoids described above. To achieve the total biosynthesis of
stilbenoids, tyrosine ammonia-lyase and phenylalanine ammonia-lyase (TAL/PAL)
and 4CL need to be added into the pathway, which will allow in situ supply of the
desired CoA starter. Wang et al. reported a stepwise increase of resveratrol
biosynthesis in S. cerevisiae to 3.44 mg/l from the amino acids in 2011 [30]. On the
other hand, it is possible to modify the structure of stilbenoids through the
introduction of some foreign enzymes to generate new derivatives. For example, a
3-O-glucosyltransferase (3-O-GT) was introduced to the resveratrol biosynthetic
pathway to generate trans-resveratrol-3-O-glucoside or trans-piceid [31].
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Curcuminoids are another group of plant phenylpropanoid metabolites, which
consist of two aromatic rings connected with a 7 carbon chain with different chemical
groups [32]. A representative member of this family is curcumin (Fig. 3). It is a
natural plant polyphenol with yellow color, and was isolated from the herb Curcuma
longa with other two derivatives demethoxycurcumin and bisdemethoxycurcumin
[33]. Curcuminoids are used as food spice (curry) and food coloring agent (E100). In
addition, they are the major bioactive components in turmeric that has been used in
traditional medicine for centuries. Curcuminoids are well-known for their anti-tumor,
anti-oxidant, anti-inflammatory, anti-allergic, and hepatoprotective activities [34-39].
The polyketide biosynthetic pathways of curcuminoids in different plants have been
investigated. Kiat et al. studied the biosynthetic pathway of curcuminoids in turmeric
using
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C-labeled precursors [40]. To gain a better understanding of curcuminoid

biosynthesis, two novel type III PKSs, diketide-CoA synthase (DCS) and curcumin
synthase (CURS), were cloned from C. longa and subjected to enzymatic studies. It
was revealed that DCS catalyzes the condensation of feruloyl-CoA and malonyl-CoA
to form feruloyldiketide-CoA, which is subsequently used by CURS to form curcumin
[41]. Two additional CURSs were discovered in the C. longa and named as CURS2
and CURS3. These two CURSs were found to have different substrate preference.
CURS2 synthesizes curcumin and demethoxycurcumin, while CURS3 has the ability
to produce curcumin, bisdemethoxycurcumin, and demethoxycurcumin [42].

7
HO

OH

H3CO

OCH3
O

OH

curcumin
Fig. 3 The structure of curcumin.

There is another way to generate curcuminoids in nature. Curcuminoid synthase
(CUS) was identified from Oryza sativa. Unlike the pathway in C. longa that requires
collaborative actions of two type III PKSs, this single PKS has the ability to
synthesize curcuminoids from malonyl-CoA and aromatic CoA esters such as
4-coumaroyl-CoA, cinnamoyl-CoA, and feruloyl-CoA [43]. The broad substrate
spectrum makes it possible to synthesize derivatives with different functional groups
and improved water solubility or bioactivity. Three curcuminoids including
dicinnamoylmethane, bisdemethoxycurcumin and cinnamoyl-p-coumaroylmethane
were produced by the engineered E. coli strain [44]. Seventeen curcumin analogs
were produced in E. coli through precursor-directed biosynthesis [45].

1.2 Objectives
The main goal of my doctoral dissertation research was to engineer natural
product biosynthetic pathways for de novo synthesis of existing or new bioactive
molecules, including phenylpropanoid acids, stilbenoids, and curcuminoids.
Additionally, I developed an in vivo reporter assay for phenylalanine ammonia-lyase.
Lastly, I investigated the biosynthetic pathway of the antibacterial natural product
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dutomycin via genome sequencing and gene disruption, and generated a promising
antibacterial agent.

Specific objectives include:
1. Construct a platform for de novo biosynthesis of various plant natural
products and their novel derivatives in E. coli.
2. Establish an in vivo reporter assay for phenylalanine ammonia-lyase.
3. Investigate the biosynthetic pathway of dutomycin and generate new
antibacterial analogs.

1.3 A guide to the dissertation
This dissertation includes five chapters. Chapter 2 and Chapter 3 describe the
engineering of a variety of plant natural product biosynthetic pathways into
Escherichia coli to generate bioactive molecules, including phenylpropanoid acids,
stilbenoids, and curcuminoids [46]. In Chapter 4, an in vivo novel and efficient visible
reporter assay was established for screening of PAL efficiency in Escherichia coli,
based on the color of a curcuminoid synthesized through this platform [47]. Finally,
Chapter 5 focuses on the study of an unknown type II polyketide biosynthetic pathway
that is responsible for the synthesis of dutomycin in Streptomyces. New compounds
were generated through rational modification of the pathway [48]. Several scientific
techniques were used in these studies, including molecular cloning, genetic
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engineering, microorganism culturing, protein expression, natural products isolation,
NMR and MS for structure determination, DNA sequence analysis, and others.
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CHAPTER 2

ENGINEERED PRODUCTION OF HYDROXYCINNAMIC ACIDS
AND STILBENOIDS IN E. COLI*

ABSTRACT
Plants produce a variety of natural products with promising biological activities,
such as phenylpropanoids and stilbenoids. While these molecules are naturally
assembled through dedicated plant metabolic pathways, combinatorial biosynthesis
has become an attractive tool to generate desired molecules. In this chapter, we
demonstrated that biosynthetic enzymes from different sources can be recombined
like legos to make various molecules. Seven biosynthetic genes from plants and
bacteria were used to establish a variety of complete biosynthetic pathways in
Escherichia coli to make valuable compounds. Different combinations of these
biosynthetic bricks were made to design rationally various natural product pathways,
yielding four phenylpropanoid acids (cinnamic acid, p-coumaric acid, caffeic acid,
and ferulic acid), three bioactive natural stilbenoids (resveratrol, piceatannol and
pinosylvin).

2.1 Introduction
Plants are a major producer of structurally diverse and medicinally important
molecules, such as resveratrol and curcumin. Resveratrol belongs to the family of
stilbene natural products, which also include piceatannol, pinosylin and other
*This chapter has been published as Wang, S., Zhang, S., Xiao, A., Rasmussen, M., Skidmore, C.,
Zhan, J.*(2015): Metabolic engineering of Escherichia coli for the biosynthesis ofvarious
phenylpropanoid derivatives. Metabolic Engineering 29,153-159.
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stilbenoids. These natural products are present in several plants such as grapes and
peanuts, but are not widely distributed in other common food sources. Interestingly,
the slight structural differences of stilbenoids may lead to different functions and
applications. For instance, resveratrol is widely used in the clinical and neutraceutical
fields due to its protection effects against a series of diseases, such as Parkinson’s,
cancer, and heart disease. It also reduces serum lipids and possesses other beneficial
effects. Recent studies demonstrated that resveratrol can significantly prolong
life-span in non-vertebrate model organisms and short-lived vertebrates [1, 2].
Piceatannol is a hydroxylated derivative of resveratrol. It naturally occurs in various
plants, including grapes, berries, passion fruit, white tea, and Japanese knotweed. It is
also a metabolic product of resveratrol in the human body. This compound has shown
strong anticancer, anti-aethrogenic, antioxidant, anti-inflammatory, antimicrobial and
estrogenic activities, which is even more potent than resveratrol [3, 4]. Like
resveratrol, piceatannol is also a bioactive component in wine, although at a much
lower concentration [4]. Pinsoylin is a dehydroxylated derivative of resveratrol and
present in the heartwood of Pinaceae. This compound is a pre-infectious fungitoxin
and protects the wood from fungal infections. It showed stronger antifungal activity
against Candida albicans and Saccharomyces cerevisiae than resveratrol [5]. These
suggested that structural modifications of these molecules may lead to new bioactive
molecules.
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In this chapter, we established a library of biosynthetic bricks with five
biosynthetic enzymes from plant, bacterial and fungal sources. These include
phenylalanine

ammonia-lyase

(PAL),

tyrosine

ammonia-lyase

(TAL),

and

4-coumarate: CoA ligase (4CL), stilbene synthase (STS), 4-coumarate 3-hydroxylase
(C3H). These enzymes were expressed or co-expressed in E. coli BL21 (DE3) in
different combinations, resulting in the production of four phenylpropanoid acids
including cinnamic acid, p-coumaric acid, caffeic acid, and ferulic acid). Introduction
of the corresponding PKS led to the total biosynthesis of three bioactive natural
stilbenoids (resveratrol, piceatannol and pinosylvin).

2.2 Materials and methods

2.2.1 General method
Products were analyzed and purified on an Agilent 1200 HPLC instrument.
ESI-MS spectra were obtained on an Agilent 6130 quadrupole LC-MS. NMR spectra
were recorded on a JEOL NMR instrument (300 MHz for 1H NMR). The chemical
shift (δ) values are given in parts per million (ppm). The coupling constants (J values)
are reported in Hertz (Hz).

2.2.2 Strains, media and culture conditions
E. coli XL1-Blue was used for routine cloning and plasmid propagation. It was
grown at 37°C on LB agar plates or in liquid LB medium supplemented with
appropriate antibiotics (ampicillin, 50 μg/ml; kanamycin, 50 μg/ml; streptomycin, 50
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μg/ml; chloramphenicol, 25μg/ml). E. coli BL21 (DE3) was used for protein
expression and compound biosynthesis. E. coli BL21 (DE3) was grown at 37°C on
LB agar plates or in liquid LB medium supplemented with appropriate antibiotics.
Enzymes were expressed in E. coli BL21 (DE3) at 28°C.

2.2.3 Gene manipulation and plasmids construction
Restriction enzymes, Phusion® High-Fidelity DNA polymerase, and T4 DNA
ligase were purchased from New England Biolabs (Ipswich, MA, USA). CloneJET™
PCR Cloning Kit was purchased from Fermentas (Glen Burnie, MD, USA), and the
pET28a, pCDFDuet-1 and pACYCDuet-1 vectors were purchased from Novagen
(Madison, WI, USA). The 4cl cDNA (GenBank accession number U18675) was
amplified from pUC-4CL1 (provided by Dr. Claudia Schmidt-Dannert, University of
Minnesota). The sts gene (GenBank accession number AB027606) was amplified
from pUC-STS (obtained from Addgene). The tal gene (GenBank accession number
ABC88669) was cloned from the S. espanaensis NRRL 15764 genomic DNA. The
c3h gene (GenBank accession number DQ357071) was amplified from S. espanaensis
NRRL 15764 genomic DNA. The comt gene (GenBank accession number 166420)
was cloned from iGEM part BBa_I742107 (provided by Dr. Charles Miller, Utah
State University). The primers are shown in Table 1. These four PCR products were
gel purified and ligated into the pJET1.2 cloning vector to yield pSW52, pSW63,
pSW87, pSW96 and pSW98 respectively (Table 2). The genes were confirmed by
digestion checks and sequencing.
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Table 1. Primers used in Chapters 2 and 3.*
Primer

Sequence

4CL1-F

5'-AACATATGGCGCCACAAGAACAAGC-3'

4CL1-R

5'-AACTCGAGTCACAATCCATTTGCTAGTTTT-3'

STS-F

5'-AAGCTAGCATGGTGTCTGTGAGTGGAAT-3'

STS-R

5'-AAGGATCCTTATATGGCCATGCTGCGGA-3'

TAL-F

5'-AACCATGGTGACGCAGGTCGTG-3'

TAL-R

5'-AAGAATTCATCCGAAATCCTTCCCGT-3'

C3H-F

5'-AACATATGACCATCACGTCACCTGC-3'

C3H-R

5'-AACTCGAGTCAGGTGCCGGG-3'

COMT-F

5'-AACTGCAGATGGGTTAACAGGTGAAA-3'

COMT-R

5'-AAGCGGCCGCTTATTAAACCTTCTTAA-3'

* Restriction sites are italicized and the start/stop codons are shown in bold.

After sequencing, the sts gene was excised from pSW63 via NheI/BamHI and
ligated to pET28a between the same sites to form pSW65. The tal gene was excised
from pSW87 via NcoI/EcoRI and introduced to the pCDFDuet-1 vector to yield
pSW95. The c3h gene was then excised from pSW96 and ligated to pSW95 between
the NdeI and XhoI sites to yield pSW97. The comt gene was cut from pSW98 with
NotI/PstI and ligated into pACYCDuet-1 vector to form pSW117 (Table 2).
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Table 2. Plasmids used in Chapters 2 and 3.
Plasmid

Description

Reference

pUC-4cl1

The 4cl cDNA from A. thaliana

(Watts et al., 2006)

pET16b-cus

The cus cDNA from O. sativa

(Katsuyama et al., 2008)

pUC-sts

The sts cDNA from A. hypogaea

Purchased from Addgene

pZJ54

rdc2 in pET28a

(Zeng and Zhan, 2010)

pSW24

cus in pET28a

(Wang et al., 2013)

pSW54

4cl in pACYCDuet-1

(Wang et al., 2013)

pSW56

pal and 4cl in pACYCDuet-1

(Wang et al., 2013)

pSW60

pal in pACYCDuet-1

(Wang et al., 2013)

pSW63

sts in pJET1.2

this work

pSW65

sts in pET28a

this work

pSW87

tal in pJET1.2

this work

pSW95

tal in pCDFDuet-1

this work

pSW96

c3h in pJET1.2

this work

pSW97

c3h and tal in pCDFDuet-1

this work

pSW98

comt in pJET1.2

this work

pSW99

comt and 4cl in pACYCDuet-1

this work

pSW117

comt in pACYCDuet-1

this work

pSW121

sts and tal in pCDFDuet-1

this work

2.2.4 Biosynthesis of hydroxycinnamic acids and stilbenoids in E. coli
Corresponding plasmids were electroporated into E. coli BL21 (DE3). The
resulting strains were grown in 50 ml of LB medium supplemented with appropriate
antibiotic(s) at 37 °C with shaking at 250 rpm. Once the OD600 reached 0.4-0.6, IPTG
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was added at a final concentration of 200 µM, and the induced culture was maintained
at 28°C with shaking at 250 rpm for an additional 5 h. Substrates (glucose and
L-phenylalanine or L-tyrosine) were added, and the culture was incubated under the
same conditions for an additional 48 h. For biotransformation, resveratrol or ferulic
acid was added as the substrate. After fermentation, 1 ml of the culture was sampled
and centrifuged at 14,000 rpm for 10 min. 100 µl of the supernatant was then
analyzed by LC-MS.

2.2.5 HPLC analysis of the biosynthesized compounds
Analysis of p-coumaric acid, caffeic acid, and ferulic acid was conducted on an
Agilent 1200 HPLC system with an Agilent Eclipse XDB-C18 column (5 μm, 250
mm × 4.6 mm). The samples were eluted with acetonitrile-water (15:85, v/v) for 25
min under 300 nm at a flow rate of 1 ml/min. Cinnamic acid was analyzed on the
same instrument, eluted with acetonitrile-water (30:70, v/v) for 25 min at 300 nm at a
flow rate of 1 ml/min. Analysis of stilbenoids were conducted on the same equipment,
eluted with a gradient of acetonitrile-water (20:80, v/v for 18 min, 20:80, v/v to 50:50
v/v from 18 min to 30 min, 50:50 v/v from 30 min to 40 min) at a flow rate of 1
ml/min. The products were detected at 330 nm. The titers of all the biosynthetic
compounds were calculated based on the standard curves of the purified compounds
or commercial samples.

2.2.6 Identification of the biosynthetic compounds
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The biosynthesized compounds were characterized by LC-MS and a comparison
with authentic samples. Resveratrol was also isolated from the fermentation broth and
subjected to NMR analysis (Appendix B).

2.3 Results

2.3.1 Engineered biosynthesis of phenylpropanoid acids in E. coli
We have cloned a total of eight genes from various sources, including pal from
Trifolium pretense (plant), tal from Saccharothrix espanaensis NRRL 15764
(bacterium), 4cl from Arabidopsis thaliana (plant), c3h from S. espanaensis NRRL
15764 (bacterium), comt from Medicago sativa (plant), sts from Arachis hypogaea
(plant). These genes constitute a tool box for combinatorial biosynthesis of a variety
of molecules.

Using a biosynthetic approach, we have successfully produced four
phenylpropanoid acids including cinnamic acid, p-coumaric acid, caffeic acid, and
ferulic acid in E. coli BL21(DE3) in high yields when 3 mM L-phenylalanine and
L-tyrosine was supplied. The compounds were characterized based on a comparison
of the ESI-MS (Fig. 4), and retention time with those of authentic samples. As shown
in Fig. 1, expression of PAL from T. pretense in E. coli yielded cinnamic acid as a
dominant product (Fig 5 trace i) at 241.3 ± 2.8 mg/l. Similarly, expression of TAL
from S. espanaensis NRRL 15764 generated p-coumaric acid from L-tyrosine in E.
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coli at 160.5 ± 2.1 mg/l (Fig 5 trace ii). Co-expression of TAL with C3H from S.
espanaensis NRRL 15764, which hydroxylates p-coumaric acid at C-3', led to the
production of caffeic acid at 70.0 ± 0.9 mg/l (Fig 5 trace iii). Further addition of
COMT from M. sativa into the system yielded ferulic acid at 28.8 ± 0.4 mg/l (Fig 5
trace iv).
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Fig. 4 ESI-MS analysis of hydroxycinnamic acids production.
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a. ESI-MS (-)

spectrum of p-coumaric acid production from L-tyrosine; b. ESI-MS (-) spectrum of
caffeic acid production from L-tyrosine; c. ESI-MS (-) spectrum of ferulic acid
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production from L-tyrosine; d. ESI-MS (-) spectrum of cinnamic acid production
from L-phenylalanine.

cinnamic acid

i

p-coumaric acid
ii
caffeic acid

iii

ferulic acid

2.5
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Fig. 5 Engineered biosynthesis of phenylpropanoid acids in E. coli. (i) HPLC analysis
of the biosynthesis of cinnamic acid by E. coli/PAL; (ii) HPLC analysis of the
biosynthesis of p-coumaric acid by E. coli/TAL; (iii) HPLC analysis of the
biosynthesis of caffeic acid by E. coli/TAL-C3H; (iv) HPLC analysis of the
biosynthesis of ferulic acid by E. coli/TAL-C3H-COMT. Mobile phase for trace i was
30% acetonitrile– water, and 15% acetonitrile–water was used for traces ii–iv. The
products were detected at 300 nm.
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2.3.2 Engineered biosynthesis of resveratrol in E. coli
Three enzymes including TAL, 4CL and STS are required to synthesize
resveratrol from the amino acid precursor. To this end, we cloned these three genes
into three expression vectors, including pET28a, pACYCDuet-1 and pCDFDuet-1, to
yield three expression plasmids, pSW54 pSW65 and pSW95 (Table 2). These
plasmids were co-expressed in E.coli BL21 (DE3). The engineered strain was grown
in LB medium. 0.6 mM L-tyrosine and 4 g/l glucose were added into the induced
culture assupplemented amino acid substrate and carbon source. As shown in Fig. 6,
LC-MS analysis revealed that a major product at 26.5 min was produced, which was
identified as resveratrol based on the ESI-MS (Fig. 6b), UV (Fig. 6c), and 1H NMR
spectra (Appendix B).

To optimize the production of resveratrol in the engineered E. coli, L-tyrosine
and glucose were fed individually or together into the induced culture. As shown in
Fig. 7a, when no nutrients were supplemented, the trace (trace ii) is same as that of
the blank control E. coli BL21 (DE3) harboring the blank vectors (trace i). When
glucose was added, resveratrol was produced by the engineered strain that harbors the
corresponding biosynthetic genes. Thus, glucose is necessary for resveratrol
biosynthesis, which provides the cells with a premium carbon source to supply the
required polyketide biosynthetic precursor malonyl-CoA. By contrast, when
L-tyrosine was supplemented, no resveratrol was detected, likely due to insufficient
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supply of malonyl-CoA. When both glucose and L-tyrosine were supplied, the
production of resveratrol was significantly improved. We next determined the optimal
concentration of L-tyrosine and glucose. As shown in Fig. 7b, the titer of resveratrol
increased with the increased concentrations of the substrates. The titer reached a
maximum when 0.6 mM L-tyrosine and 4 g/l glucose were added. Further increase in
the concentrations of these substrates did not lead to any improvements of resveratrol
biosynthesis. However, the intermediate p-coumaric acid started to accumulate. The
highest titer of resveratrol was determined to be 114.4 ± 3.5 mg/l.
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Fig. 6 LC-MS analysis of resveratrol production. a. the HPLC trace of resveratrol
production from Tyrosine; b. ESI-MS (+) spectrum of resveratrol production from
tyrosine; c. UV spectrum of resveratrol production from tyrosine.
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Fig. 7 Condition optimization for resveratrol production. a. different substrates
condition for resveratrol production ( i: Tyr, glucose feeding; ii: glucose feeding; iii:
Tyr feeding; iv: none feeding control; v: blank vectors in BL21(DE3) with Tyr,
glucose feeding control.); b. different substrates concentration (i: 0 mM Tyr, 0g/l
glucose; ii: 0.3 mM Tyr, 2g/l glucose; iii: 0.6 mM Tyr, 4 g/l glucose; iv 1.5 mM Tyr,
10 g/l glucose; v: 3mM Tyr, 20 g/l glucose).

2.3.3 Engineered biosynthesis of piceatannol and pinosylvin in E.coli
Using the library of biosynthetic bricks constructed above, we next made two
resveratrol analogs. Piceatannol is a natural resveratrol analog with an additional
phenolic hydroxyl group at C-3'. To make this compound, we first employed a
biotransformation approach using a C3H from S. espanaensis NRRL 15764. This
enzyme was used to create caffeic acid and ferulic acid above, which indicated that it
can introduce a hydroxyl group to p-coumaric acid at C-3'. However, it was unclear
whether it could accept resveratrol as the substrate. To test whether this enzyme can
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hydroxylate resveratrol at C-3', C3H was then individually expressed in E. coli BL21
(DE3). The IPTG-induced broth was incubated with resveratrol. LC-MS revealed that
a major product at 15.5 min was generated by the engineered E. coli BL21 (DE3)
strain, together with the substrate resveratrol at 26.5 min (trace ii, Fig. 8). The product
was characterized as piceatannol by a comparison of the retention time, ESI-MS
(Appendix B) spectra with those of the commercial standard of piceatannol.
Conversion of resveratrol to piceatannol revealed the broad substrate specificity of
this C3H. The titer of piceatannol from this biotransformation process was 65.4 ± 1.0
mg/l.

Total biosynthesis of piceatannol has never been reported. We next constructed a
biosynthetic pathway of this natural product by introducing C3H into the resveratrol
biosynthetic pathway. To this end, TAL, 4CL, C3H and STS were co-expressed in E.
coli BL21 (DE3). LC-MS analysis revealed that a major product was synthesized
from L-tyrosine. The retention time (trace iii, Fig. 8), UV and ESI-MS of this product
were consistent with those of the authentic sample of piceatannol, confirming that a
complete biosynthetic pathway of piceatannol was successfully constructed in E. coli.
The titer of piceatannol from this total biosynthetic pathway was determined to be
21.5 ± 0.2 mg/l.
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Pinosylvin is another natural resveratrol analog that lacks a hydroxyl group at C-4.
The biosynthesis of this compound has never been studied. Based on its structure, we
proposed that the biosynthetic pathway of this molecule is similar to that of
resveratrol. To synthesize this compound, L-phenylalanine should be used as the
starting amino acid precursor. Thus，we need a PAL to convert L-phenylalanine to
cinnamic acid. However, successful biosynthesis of pinosylvin also requires the
ability of 4CL and STS to accept “unnatural” substrates, meaning that 4CL can ligate
cinnamic acid with CoA to yield cinnamoyl-CoA and STS can take cinnamoyl-CoA
as the starter unit. To test this, we co-expressed PAL, 4CL and STS in E. coli BL21
(DE3). LC-MS analysis revealed that a major metabolite at 34.5 min was produced
(trace iv, Fig. 8). The ESI-MS spectrum showed an ion peak [M-H]- at m/z 211
(Appendix B), suggesting that the molecular weight of this compound is 212. The UV
spectrum (Appendix B) and retention time of this product were same as those of the
commercial standard of pinosylvin. Therefore, we were able to for the first time
establish the complete pinosylvin biosynthetic pathway in E. coli.

The titer of

pinosylvin was determined to be 13.3 ± 0.8 mg/l.

2.4 Conclusion
In this chapter, we established a library of biosynthetic bricks with five
biosynthetic enzymes from different sources, including PAL, TAL, 4CL, STS and
C3H. These enzymes were expressed or co-expressed in E. coli BL21 (DE3) in
different combinations, resulting in the production of four phenylpropanoid acids
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(cinnamic acid, p-coumaric acid, caffeic acid, and ferulic acid). Introduction of the
corresponding PKS led to the total biosynthesis of three bioactive natural stilbenoids
(resveratrol, piceatannol and pinosylvin). The results from this chapter provided
important platforms and technical basis for further engineering polyketide biosynthetic
pathways for producing valuable bioactive molecules.

Fig. 8 Engineered biosynthesis of resveratrol analogs in E. coli.(i) HPLC analysis of
the biosynthesis of resveratrol by E. coli/TAL-4CL-STS; (ii) Conversion of
resveratrol to piceatannol by E. coli/C3H through the specific C-3' hydroxylation; (iii)
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HPLC analysis of the biosynthesis of piceatannol by E. coli/TAL-4CL-STS-C3H; (iv)
HPLC analysis of the biosynthesis of pinosylvin by E. coli/PAL-4CL-STS.The
products were detected at 330 nm.
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CHAPTER 3

ENGINEERED PRODUCTION OF CURCUMINOID AND TWO
UNNATURAL ANALOGS IN E.COLI*

ABSTRACT
Curcuminoid, which is produced specifically by the expression of curcuminoid
synthase (CUS) gene, has long been used as traditional Asian medicines because of its
reported activities on anti-tumor, antioxidant and hepatoprotective. Hence, CUS gene
is an attractive target for metabolic engineering. In this chapter, we modified the
library of biosynthetic bricks mentioned in Chapter 2 with eight biosynthetic enzymes
from plant, bacterial and fungal sources, which resulted in producing three natural
curcuminoids

(curcumin,

bisdemethoxycurcumin

and

dicinnamoylmethane).

Remarkably, a curcumin analog dicafferolmethane was synthesized by removing a
methyltransferase from the curcumin biosynthetic pathway. Furthermore, introduction
of a fungal flavin-dependent halogenase into the resveratrol biosynthetic pathway
yielded a novel chlorinated molecule 2-chloro-resveratrol. This work thus provided a
novel and efficient biosynthetic approach to create various bioactive molecules.
Further expansion of the library of the biosynthetic bricks will provide a resource for
rational design of various phenylpropanoids via the combinatorial biosynthesis
approach.

3.1 Introduction
* This chapter has been published as Wang, S., Zhang, S., Xiao, A., Rasmussen, M., Skidmore, C.,
Zhan, J.*(2015): Metabolic engineering of Escherichia coli for the biosynthesis of various
phenylpropanoid derivatives. Metabolic Engineering 29, 153-159.
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Curcuminoids are another family of plant polyphenols, exemplified by curcumin,
a major component in turmeric. Turmeric has long been used as a food spice (curry)
and complementary and alternative medicine (CAM) in Asia [1-4]. These compounds
possess various bioactivities and can be used for the treatment of different diseases
such as allergy, asthma, cancer and Alzheimer's disease, while providing prevention
against oxidative damage in normal cells [5-9].

The above-mentioned natural products are assembled through well designed plant
metabolic pathways. These compounds are traditionally extracted from the
corresponding producing plants. Given the long growth period of plants, this is neither
efficient nor cost-effective. Development of synthetic biology and metabolic
engineering techniques provides a great opportunity to synthesize these molecules in
microorganisms. Some progresses have been made in engineered biosynthesis of plant
natural products such as coumarins [10, 11] in microorganisms. Resveratrol has also
been produced in the yeast Saccharomyces cerevisiae, although the yield was only 6
mg/l [12, 13]. However, there is no report on total biosynthesis of piceatannol or
pinsoylin. The biosynthesis of curcumin has also been studied. Two type III
polyketide synthases (PKSs), diketide-CoA synthase (DCS) and curcumin synthase
(CURS), are involved in the biosynthesis of curcuminoids in the herb Curcuma longa
[14]. Compared to the collaborative actions of two type III PKSs in C. longa, one
single type III PKS from Oryza sativa, curcuminoid synthase (CUS), was found to
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synthesize curcuminoids. With supplementation of different carboxylate precursors,
curcumin and several analogs were synthesized in E. coli [15]. However, total
biosynthesis of curcumin from an amino acid precursor has not been reported.

In this chapter, we modified the library of biosynthetic bricks mentioned in
chapter 2 with eight biosynthetic enzymes from plant, bacterial and fungal sources.
These include phenylalanine ammonia-lyase (PAL), tyrosine ammonia-lyase (TAL),
4-coumarate:CoA ligase (4CL), stilbene synthase (STS), CUS, 4-coumarate
3-hydroxylase

(C3H),

caffeic

acid

3-O-methyltransferase (COMT), and a

flavin-dependent halogenase Rdc2. Introduction of the corresponding PKS led to
three

natural

curcuminoids

(curcumin,

bisdemethoxycurcumin

and

dicinnamoylmethane). Remarkably, we also generated two novel molecules by
constructing a new curcuminoid biosynthetic pathway and adding a fungal halogenase
to the resveratrol pathway, respectively. This work thus demonstrated a highly
efficient

combinatorial

biosynthesis

approach

to

creating

various

plant

phenylpropanoids in E. coli.

3.2 Materials and methods

3.2.1 General method
Products were analyzed and purified on an Agilent 1200 HPLC instrument.
ESI-MS spectra were obtained on an Agilent 6130 quadrupole LC-MS. NMR spectra
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were recorded on a JEOL NMR instrument (300 MHz for 1H NMR). The chemical
shift (δ) values are given in parts per million (ppm). The coupling constants (J values)
are reported in Hertz (Hz).

3.2.2 Strains, media and culture conditions
E. coli XL1-Blue was used for routine cloning and plasmid propagation. It was
grown at 37°C on LB agar plates or in liquid LB medium supplemented with
appropriate antibiotics (ampicillin, 50 μg/ml; kanamycin, 50 μg/ml; streptomycin, 50
μg/ml; chloramphenicol, 25μg/ml). E. coli BL21 (DE3) was used for protein
expression and compound biosynthesis. E. coli BL21 (DE3) was grown at 37°C on
LB agar plates or in liquid LB medium supplemented with appropriate antibiotics.
Enzymes were expressed in E. coli BL21 (DE3) at 28°C.

3.2.3 Gene manipulation and plasmids construction
Based on the work in chapter 2, the comt gene was cut from pSW98 with
NotI/PstI and ligated into pSW54 between the same sites, yielding pSW99. The sts
was introduced to pSW95 to form pSW121 via the MefI/XhoI sites. Construction of
pSW24, pSW54, pSW56, pSW60 and pZJ54 has been reported in our previous studies
[16, 17].

3.2.4 Biosynthesis of hydroxycinnamic acids and stilbenoids in E. coli
Corresponding plasmids were electroporated into E. coli BL21 (DE3). The
resulting strains were grown in 50 ml of LB medium supplemented with appropriate
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antibiotic(s) at 37C with shaking at 250 rpm. Once the OD600 reached 0.4-0.6, IPTG
was added at a final concentration of 200 µM, and the induced culture was maintained
at 28°C with shaking at 250 rpm for an additional 5 h. Substrates (glucose and
L-phenylalanine or L-tyrosine) were added, and the culture was incubated under the
same conditions for an additional 48 h. For biotransformation, resveratrol or ferulic
acid was added as the substrate. After fermentation, 1 ml of the culture was sampled
and centrifuged at 14,000 rpm for 10 min. 100 µl of the supernatant was then
analyzed by LC-MS.

3.2.5 HPLC analysis of the biosynthesized compounds
Analysis of stilbenoids were conducted on the same equipment, eluted with a
gradient of acetonitrile-water (20:80, v/v for 18 min, 20:80, v/v to 50:50 v/v from 18
min to 30 min, 50:50 v/v from 30 min to 40 min) at a flow rate of 1 ml/min. The
products were detected at 330 nm. Curcuminoids were analyzed on the same
equipment, eluted with a gradient of acetonitrile-water (from 10:90, v/v to 100:0, v/v
over 30 min) at a flow rate of 1 ml/min. The products were detected at 420 nm. The
titers of all the biosynthetic compounds were calculated based on the standard curves
of the purified compounds or commercial samples.

3.2.6 Identification of the biosynthetic compounds
The biosynthesized compounds were characterized by LC-MS and a comparison
with authentic samples. Curcumin, 2-chloro-resveratrol and dicafferolmethane were
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also isolated from the fermentation broth and subjected to NMR analysis (Appendix
C).

3.3 Results

3.3.1 Engineered biosynthesis of curcumin and two analogs in E. coli
The biosynthesis of curcuminoids has been previously studied. Curcuminoids
including

bisdemethoxycurcumin,

dicinnamoylmethane

and

cinnamoyl-p-

coumaroylmethane have been synthesized in E. coli that harbors PAL from the yeast
Rhodotorula rubra, 4CL from Lithospermum erythrorhizon and CUS from O. sativa,
in the presence of L-phenylalanine or L-tyrosine. Curcumin was also synthesized by
CUS and 4CL in E. coli when ferulic acid was supplied as a substrate. However, total
biosynthesis of curcumin from the amino acid precursor has not been achieved. We
have co-expressed PAL from T. pretense, 4CL from A. thaliana and CUS from O.
sativa in E. coli to generate the curcumin analog dicinnamoylmethane in our previous
study (trace i, Fig. 9) [16]. This confirmed that CUS was functional in our system and
it is possible to make curcuminoids directly from the amino acid precursor. We first
replaced PAL with TAL in the dicinnamolymethane biosynthetic pathway.
Accordingly, co-expression of TAL, 4CL and CUS yielded a major product at 17.7
min (trace ii, Fig.9). The ion peak [M-H]- at m/z 307.0 in the ESI-MS spectrum (Fig.
10b) indicated the molecular weight of this product is 308. The retention time and UV
spectrum

(Fig.

10a)

were

consistent

with

those

of

the

standard

of
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bisdemethoxycurcumin. Thus, we were able to construct a complete biosynthetic
pathway for bisdemethoxycurcumin, which co-exists with curcumin in turmeric. This
compound is a minor bioactive component of turmeric and a common impurity in the
commercial product of curcumin. The titer of bisdemethoxycurcumin was determined
to be 28.9 ± 1.0 mg/l. Our method thus provides an efficient way to produce this
minor constituent of turmeric.

Fig. 9 Engineered biosynthesis of curcuminoids in E. coli. (i) HPLC analysis of the
biosynthesis of dicinnamoylmethane by E. coli/PAL-4CL-CUS; (ii) HPLC analysis of
the biosynthesis of bisdemethoxycurcumin by E. coli/TAL-4CL-CUS; (iii) HPLC
analysis of the biosynthesis of curcumin by E. coli/4CL-CUS from ferulic acid; (iv)
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HPLC analysis of the total biosynthesis of curcumin from L-tyrosine by E. coli/
TAL-C3H-COMT-4CL-CUS.The products were detected at 420 nm.

We next attempted to establish a complete biosynthetic pathway of curcumin in E.
coli. We first tested whether 4CL from A. thaliana can ligate ferulic acid with CoA to
yield feruloyl-CoA, the starter unit for curcumin biosynthesis. The cus and 4cl genes
were respectively ligated to two expression vectors and co-expressed in E. coli BL21
(DE3). Ferulic acid was supplemented into the IPTG-induced culture of the
engineered strain. HPLC analysis revealed a major product at 18.5 min (trace iii, Fig.
9). The molecular weight of the peak was determined to be 368 based on the
quasimolecular ion peak [M-H]- at m/z 367.0 in the ESI-MS spectrum (Fig. 10d). The
UV spectrum of this product (Fig. 10c) was same as that of the authentic sample of
curcumin. The compound was isolated from the broth and subjected to 1H NMR
analysis (Appendix C), which confirmed that this product was curcumin. Thus, we
proposed that 4CL from A. thaliana could convert ferulic acid to feruloyl-CoA in our
expression system. Because we have made ferulic acid using TAL, C3H and COMT
in E. coli, we propose that co-expression of these enzymes with 4CL and CUS should
yield curcumin. The five genes were then ligated to three expression vectors to yield
pSW24, pSW97 and pSW99 (Table 2). Co-expression of these plasmids in E. coli
cells yielded curcumin (trace iv, Fig. 9). Therefore, a total biosynthetic pathway of
curcumin was established in E. coli. The titer of this compound was determined to be
0.6 ± 0.1 mg/l.
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production from tyrosine; d. ESI-MS (-) spectrum of curcumin production from
tyrosine.

3.3.2 Engineered biosynthesis of novel resveratrol and curcumin analogs in E. coli
With the library of eight biosynthetic genes, we further expanded their uses for
combinatorial biosynthesis of novel molecules. Because halogenated compounds
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account for a quarter of the current drugs or those in the development pipeline, it will
be of significant interest to generate halogenated molecules for bioactivity screening.
To achieve this goal, we selected a fungal flavin-dependent halogenase Rdc2, which
was characterized in our previous studies as the dedicated halogenase in radicicol
biosynthesis [17]. This enzyme has broad-substrate specificity. As shown in trace i of
Fig. 11, co-expression of TAL, 4CL, STS and Rdc2 in E. coli BL21 (DE3) yielded a
new product at 30 min in addition to resveratrol. The molecular weight of this new
product was found to be 262 based on the ion peaks [M-H]- at m/z 261 and 263 (3:1)
and [M+Cl]- at m/z 297 (Fig. 12a). The ratio of 3:1 is a characteristic isotope pattern
of monochlorinated molecule. Compared to resveratrol, a bathochromic shift was
observed in the UV spectrum of the product (Fig. 12b). Thus, the product was
deduced to be a chlorinated derivative of resveratrol. This compound was then
purified and subjected to 1H NMR analysis (Appendix), based on which it was
identified as 2-chloro-resveratrol. The titer was determined to be 7.0 ± 0.3 mg/l.

Commercially available curcumin product prepared from the herb Curcuma longa
usually

contains

77%

curcumin,

17%

demethoxycurcumin

and

3%

bisdemethoxycurcumin. However, no naturally occurring demethylated derivatives of
curcumin are known. Given the poor water solubility of curcumin, demethylation of
curcumin may represent an effective way to increase its polarity and water solubility.
To this end, we constructed a new biosynthetic pathway with TAL, C3H, 4CL and
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CUS so that a new demethylated curcumin analog can be generated with
caffeoyl-CoA as the starter unit. These enzymes were co-expressed in E. coli BL21
(DE3). HPLC analysis revealed a dominant product at 14.8 min (trace ii, Fig. 11). Its
molecular weight was determined to be 340 based on the [M-H]- ion peak at m/z
339.1 (Fig. 12c). It was 28 mass units less than curcumin, suggesting that it is a
didemethylated analog of curcumin. This was supported by the UV spectrum of this
compound, which is similar to that of curcumin. The product was then purified and
subjected to NMR analysis (Appendix C), based on which it was characterized as
dicafferolmethane. [18] The titer was determined to be 2.8 ± 0.5 mg/l.

Fig. 11 Engineered biosynthesis of novel resveratrol and curcumin analogs in E. coli.
(i)

HPLC

analysis

of

the

biosynthesis

of

2-chloro-resveratrol

by

E.
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coli/TAL-4CL-STS- Rdc2 at 330nm; (ii) HPLC analysis of the biosynthesis of
dicaffeoylmethane by E. coli/TAL-C3H-4CL-CUS at 420 nm.
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3.4 Conclusion
Natural products are a major source of new drugs. Numerous structures have been
discovered from Nature, such as the well-known anticancer drug paclitaxel. The
molecules are assembled through well designed biosynthetic pathways that consist of
a series of collaborative biosynthetic enzymes. Plant natural products are traditionally
extracted from the producing species. This process is inefficient since it takes long
time from seeding to harvest. Although some natural product biosynthetic pathways
from plants have been reported, direct engineering of these pathways in plants are
technically challenging and time-consuming. Recent development in genome
sequencing and synthetic biology has provided a unique opportunity to construct
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artificial biosynthetic pathways in a heterologous host to generate plant natural
products or novel structures. This work systematically demonstrated that a variety of
biosynthetic pathways (Fig. 13) can be constructed based on eight biosynthetic
enzymes to yield a number of biologically relevant molecules.

We made a small library of biosynthetic genes that were from different sources
(plant, bacterial and fungal). Using a multiple-vector approach, these biosynthetic
bricks can be combined in different ways to yield desired molecules. In
phenylpropanoid biosynthesis, amino acids are first converted to various carboxylic
acid precursors, which serve as the starter units for the following polyketide chain
elongation. These phenylpropanoid acids include cinnamic acid, p-coumaric acid,
caffeic acid, and ferulic acid. Some of these acids such as caffeic acid have also
shown antioxidant activity [3]. In addition, these acids also show inhibitory activity
on intestinal alpha-glucosidase activity, which delays the digestion of starch and
disaccharides to absorbable monosaccharides and may help reduce postprandial
hyperglycemia [19]. These compounds are synthesized from amino acids including
L-phenylalanine and L-tyrosine. The simplest biosynthetic pathways constructed in
this work were the production of p-coumaric acid (Fig. 13A, 160.5 ± 2.1 mg/l) and
cinnamic acid (Fig. 13B, 241.3 ± 2.8 mg/l), which were synthesized from L-tyrosine
by TAL and L-phenylalanine by PAL, respectively. While both enzymes showed high
efficiency, the difference in the titer of these acids indicated that PAL might work
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more efficiently than TAL in E. coli. p-Courmaic acid can be hydroxylated by C3H,
as revealed by the production of caffeic acid at 70.0 ± 0.9 mg/l by E. coli/TAL-C3H
(Fig. 13A). The titer of the final product decreased when an additional step was
introduced to the pathway. This result was further supported by the production of
ferulic acid (Fig. 13A) by E. coli/TAL-C3H-COMT at 28.8 ± 0.4 mg/l when the third
enzyme COMT was introduced. Increasing the expression level of enzymes for the
late steps may help increase the overall efficiency of such multi-step biosynthetic
pathways.

With the pool of the eight biosynthetic enzymes, more complex biosynthetic
pathways were constructed to generate a series of bioactive plant natural products.
While resveratrol biosynthesis has been reconstituted in E. coli in previous studies,
the total biosynthesis of piceatannol and pinosylvin was achieved for the first time in
this work. The biosynthetic pathway of pinosylvin was rationally designed based on
its structural similarity to resveratrol, and successfully established by taking
advantage of the substrate flexibility of both 4CL and STS. The biosynthesis of
piceatannol was constituted by the introduction of a C3H into the resveratrol
biosynthetic pathway. This C3H represents a flexible hydroxylase with broad
substrate specificity. It not only hydroxylates p-coumaric acid at C-3' to yield caffeic
acid, but also converts resveratrol to piceatannol by the hydroxylation at the same
position. A recent work reported that a non-P450 monooxygenase (HpaBC) from E.
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coli can also hydroxylate resveratrol at the same position [20]. Production of
pinosylvin and piceatannol provides in E. coli an efficient way to produce these plant
natural products. More complex biosynthetic pathways were constructed using the
pool of biosynthetic enzymes to yield a series of curcuminoids. Collaborative actions
of five enzymes including TAL, 4CL, C3H, COMT and CUS in E. coli resulted in the
total biosynthesis of the pharmaceutically important molecule curcumin.

We also demonstrated the feasibility of rational design of new molecules, either
by removal or addition of an enzyme from a particular biosynthetic pathway. For
example, removal of COMT from the curcumin biosynthetic pathway leaves the 8and 8'-OH unmethylated, leading to the production of the curcumin analog
dicafferolmethane. When a halogenase Rdc2 was added to the resveratrol biosynthetic
pathway, a novel chlorinated analog of resveratrol was produced. This molecule has
been previously chemically synthesized [18]. However, chemical preparation of
chlorinated is limited by the lack of selection. In this constructed pathway, Rdc2 can
specifically introduce a chlorine atom at C-2, further indicating that this enzyme has
broad substrate specificity. 2-Chloro-resveratrol has shown stronger antioxidant and
antimicrobial activity than resveratrol [18].

In summary, we used a simple set of eight biosynthetic enzymes to achieve the
biosynthesis of 12 phenylpropanoids in E. coli. More structures can be easily
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produced by varying the combinations of these enzymes. For example, co-expression
of TAL, 4CL, C3H, STS and Rdc2 in E. coli is expected to generate
2-chloro-piceatannol. Functional expression of the biosynthetic enzymes in E. coli is
required, while substrate flexibility of these enzymes is preferred as this will
significantly increase the number of possible pathways that can be constructed.
Further expansion of this library of biosynthetic “legos” will yield a huge resource to
produce pharmaceutically important molecules in a fast-growing host or synthesize
novel compounds for bioactivity screening.
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Fig. 13 Combinatorial biosynthesis of plant natural products and their analogs in E.
coli from L-tyrosine (A) and L-phenylalanine (B) using biosynthetic bricks from
different sources.
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CHAPTER 4

DESIGN AND APPLICATION OF AN IN VIVO REPORTER

ASSAY FOR PHENYLALANINE AMMONIA-LYASE *

ABSTRACT
Phenylalanine ammonia-lyase (PAL) is an important enzyme that links primary
metabolism to secondary metabolism. Its efficiency is often a critical factor that
affects the overall flux of a related metabolic pathway, the titer of the final products,
and the efficacy of PAL-based therapies. Thus, PAL is a common target for metabolic
engineering and it is of significant interest to screen efficient PALs for industrial and
medical applications. In this study, a novel and efficient visible reporter assay for
screening of PAL efficiency in E. coli was established based on a plant type III
polyketide biosynthetic pathway. The candidate PALs were co-expressed with a
4-coumarate:CoA ligase 4CL1 from Arabidopsis thaliana and curcuminoid synthase
(CUS) from Oryza sativa in E. coli BL21(DE3) to form a dicinnamoylmethane
biosynthetic pathway. Taking advantage of the yellow color of the product, a
microplate-based assay was designed to measure the titer of dicinnamoylmethane,
which was validated by HPLC analysis. The different titers of the product reflect the
overall performance (expression and enzymatic efficiency) of the individual PALs in
E. coli. Using this system, we have screened three PALs (PAL1, PAL3 and PAL4)
from Trifolium pratense, among which PAL1 showed the best performance in E. coli.
The engineered E. coli strain containing PAL1, 4CL1 and CUS led to the production
*This chapter has been published as Wang, S., Zhang, S., Zhou, T., Zeng, J., Zhan, J.* (2013): Design
and application of an in vivo reporter assay for phenylalanine ammonia-lyase. Applied Microbiology
and Biotechnology 97, 7877–7885.
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of

dicinnamoylmethane

at

a

high

level

of

0.36g/l.

Supplement

of

2-fluoro-phenylalanine yielded two fluorinated dicinnamoylmethane derivatives, 6,
6’-difluoro-dicinnamoylmethane and 6-fluoro-dicinnamoylmethane, of which the
latter is a new curcuminoid.

4.1 Introduction
Phenylalanine ammonia-lyase (PAL, EC 4.3.1.5) catalyzes the conversion of
phenylalanine (Phe) to trans-cinnamic acid and ammonia through deamination. It is
considered to be an essential linker between the primary metabolism and secondary
metabolism [1, 2] as it is involved in both amino acid metabolism and natural product
biosynthetic pathways. Because of its importance in different metabolic pathways,
PAL has gained considerable significance in medical, industrial, and biotechnological
applications [3]. Since its discovery in 1961[4], PAL has been extensively
investigated. Many PAL genes have been discovered from plants and microorganisms
and some of the structures have been solved [5, 6].

PAL is a potential agent in the treatment of phenylketonuria, an autosomal
recessive genetic disorder that results in an inability to metabolize Phe and elevated
levels of this amino acid in the bloodstream, which can cause severe mental
retardation. Oral or subcutaneous administration of PAL led to substantial lowering of
plasma and brain Phe levels [7-9]. With further improvement of the stability, this
enzyme can be used in enzyme substitution therapy of phenylketonuria. PAL was
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used in industry to produce L-Phe from trans-cinnamic acid by taking advantage of
the reversal of the physiological reaction [10]. A PAL from Rhodotorula glutinis can
directly convert trans-cinnamic acid methyl ester to L-Phe methyl ester, which
eliminates the need for chemical esterification of L-Phe with methanol in aspeartame
synthesis [11]. PAL is also frequently observed in secondary metabolic pathways that
lead to the formation of various natural products such as enterocin in the marine
bacterium Streptomyces maritimus [12] and phenylpropanoids in plants [13] including
flavonoids, isoflavonoids, coumarins, stilbenes, hydroxycinnamic acids, lignin, and
other phenolic compounds. In addition to serving as regulatory or signaling molecules
in plants [14], many of these natural products have also displayed promising
biological activities such as antioxidant, antimicrobial and anti-inflammatory
properties. PAL catalyzes the first biosynthetic step of phenylpropanoid products and
plays a key regulatory role in controlling the biosynthesis of these natural products. Its
efficiency is important for carbon flux into these pathways and directly influences the
yields of the final products. Thus, PAL has become a critical metabolic engineering
target for many natural product biosynthetic pathways.

Curcuminoids are a group of plant phenylpropanoid natural products, exemplified
by curcumin, and have long been used as a traditional Asian medicine because of their
anti-tumor, antioxidant, anti-inflammatory, anti-allergy and hepatoprotective activities
[15-24]. They are also the major constituents in curry spice that is widely used in
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various foods. Recently, curcuminoids have been found to be synthesized by type III
polyketide synthases (PKSs) in plants. Two type III PKSs, diketide-CoA synthase
(DCS) and curcumin synthase (CURS), are involved in the biosynthesis of
curcuminoids in the herb Curcuma longa. DCS takes feruloyl-CoA and malonyl-CoA
to synthesize feruloyldiketide-CoA, which is further converted into curcumin by
CURS [25]. When other substrates such as 4-coumaryol-CoA are taken, different
curcuminoids can be formed. In contrast to the collaborative actions of two type III
PKSs in C. longa, an individual type III PKS from Oryza sativa, curcuminoid
synthase (CUS), was found to synthesize curcuminoids from aromatic CoA starters
and malonyl-CoA. CUS has been functionally expressed in Escherichia coli. Its
co-expression with PAL from Rhodotorula rubra and 4-coumarate: CoA ligase (4CL)
from Lithospermum erythrorhizon has led to the production of plant-specific
curcuminoids in E. coli [26]. The engineered strain was also utilized to produce
unnatural curcuminoids by providing a variety of carboxylate precursors [27].

In spite of the importance of PAL, there is no efficient screening assay for this
type of enzyme. The yellow color makes curcuminoids potential reporter molecules.
In this study, we established a novel and efficient visible screening assay for efficient
PALs in an E. coli system based on the curcuminoids biosynthetic pathway. The
overall performance of a PAL is reflected in the titer of dicinnamoylmethane (1, Fig.
14) that can be easily detected by eyes and measured by a UV-Vis microplate reader.
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Using this system, we have compared the efficiency of three PALs from Trifolium
pratense and found that PAL1 showed the highest efficiency in E. coli. The
collaborative work of PAL1 with 4CL1 from Arabidopsis thaliana and CUS from O.
sativa led to the high-yield production of 1 in E. coli. Supplement of 2-fluoro-L-Phe
into the fermentation broth yielded two fluorinated dicinnamoylmethane derivatives,
6-fluoro-dicinnamoylmethane (2, Fig. 14) and 6,6'-difluoro-dicinnamoylmethane (3,
Fig. 14). 2 is a new compound.

Fig. 14 Curcuminoids (1-3) synthesized in E. coli. 1 was synthesized from L-Phe.

4.2 Materials and methods

4.2.1 General method
Products were analyzed and purified on an Agilent 1200 HPLC instrument.
ESI-MS spectra were acquired on an Agilent 6130 quadrupole LC-MS in the positive
mode. NMR spectra were recorded in acetone-d6 on a JEOL NMR instrument (300
MHz for 1H NMR and 75 MHz for 13C NMR). The chemical shift (δ) values are
given in parts per million (ppm). The coupling constants (J values) are reported in
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Hertz (Hz). The titers of 1 were analyzed on a SpectraMax® 190 Absorbance Plate
Reader (Molecular Devices, CA, USA) and an Agilent 1200 HPLC system.

4.2.2 Bacterial strains and materials
E. coli XL1-Blue was utilized for routine cloning and plasmid propagation. E.
coli BL21 (DE3) was used for protein expression and the designed reporter assay. All
E. coli strains were grown at 37 °C on LB agar plates or in liquid LB medium
supplemented with appropriate antibiotics (ampicillin, 50µg/ml; kanamycin, 50µg/ml;
chloramphenicol, 25µg/ml; Gold Biotechnology, MO, USA). Restriction enzymes,
Phusion® High-Fidelity DNA polymerase, and T4 DNA ligase were purchased from
New England Biolabs (Ipswich, MA, USA). CloneJET™ PCR Cloning Kit was from
Fermentas (Glen Burnie, MD, USA), and the pET28a and pACYCDuet-1 vectors
were purchased from Novagen (Madison, WI, USA). The plasmids including
pMLS252-PAL1, pMLS252-PAL3 and pMLS252-PAL4 that contain the cDNAs of
PALs were gifts from Dr. Mike Sullivan from USDA. The plasmids pUC-4CL1
(containing the cDNA of 4CL1 from A. thaliana) and pET16b-CUS (containing the
cDNA of CUS from O. sativa) were respectively provided by Dr. Claudia
Schmidt-Dannert at the University of Minnesota and Dr. Nobutaka Funa at the
University of Shizuoka, Japan.

4.2.3 Gene amplification and plasmids construction
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The cDNAs encoding PAL1 (GenBank accession number DQ073809), PAL3
(GenBank accession number DQ073808) and PAL4 (GenBank accession number
DQ073811) were amplified with Phusion® High-Fidelity DNA polymerase from
pMLS252-PAL1, pMLS252-PAL3 and pMLS252-PAL4, respectively. A 30-cycle
polymerase chain reaction (PCR) program (60 s at 98 °C, 60 s at 68 °C and 150 s at
72 °C) was used. The 4CL1 cDNA (GenBank accession number U18675) was
amplified from pUC-4CL1 using a 30-cycle PCR program (60 s at 98 °C, 60 s at
62 °C and 135 s at 72 °C). The primers are shown in Table 3. These four PCR
products were gel-purified and ligated into the pJET1.2 cloning vector to yield
pSW48, pSW49, pSW50 and pSW52 (Table 4). The genes were confirmed by
digestion checks and sequencing.

The CUS gene (GenBank accession number Q8LIL0) was excised from
pET16b-CUS with NdeI and BamHI and ligated into pET28a between the same sites,
yielding pSW24. The 4CL1 gene was excised from pSW52 with NdeI and XhoI and
ligated into pACYCDuet-1 between the same sites, yielding pSW54. The PAL1,
PAL3 and PAL4 genes were excised with PstI and NotI from pSW48, pSW49 and
pSW50, respectively, and ligated to pSW54 between the same sites to yield pSW56,
pSW57 and pSW58 (Table 4).
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Table 3. Primers used in Chapter 4.*
Primer

Sequence

PAL1-F

5'-AACTGCAGATGGAGGGAATTACCAATGG-3'

PAL1-R

5'-AAGCGGCCGCTCAACATATTGGAAGA-3'

PAL3-F

5'-AACTGCAGATGGAAGCAGTAGCAGCA-3'

PAL3-R

5'-AAGCGGCCGCTTAACAAATTGGAAGA-3'

PAL4-F

5'-AACTGCAGATGGAAGCAGAGCATCAGC-3'

PAL4-R

5'-AAGCGGCCGCTTAACATATTGGAAGAG-3'

4CL1-F

5'-AACATATGGCGCCACAAGAACAAGC-3'

4CL1-R

5'-AACTCGAGTCACAATCCATTTGCTAGTTTT-3'

PAL-RT-F

5'-CCATGTTTACCACTTCGCG-3'

PAL-RT-R

5'-AGAACAATAGAAGCTAAACCAGAAC-3'

16S-RT-F

5'-CTCCTACGGGAGGCAGCAG-3'

16S-RT-R

5'-GWATTACCGCGGCKGCTG-3'

* Restriction sites are italicized and the start/stop codons are shown in bold.
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Table 4. Plasmids used in Chapter 4.

Plasmid

Description

Reference

pMLS252-pal1

The intron-free PAL1gene from T.
pratense

(Sullivan 2009)

pMLS252-pal3

The intron-free PAL3 gene from T.
pratense

(Sullivan 2009)

pMLS252- pal4

The intron-free PAL4 gene from T.
pratense

(Sullivan 2009)

pUC-4cl1

The 4CL1 cDNA from A. thaliana

(Watts et al. 2006)

pET16b-cus

The CUS cDNA from O. sativa

(Katsuyama et al.
2007)

pSW24

CUS in pET28a

this work

pSW48

PAL1 in pJET1.2

this work

pSW49

PAL3 in pJET1.2

this work

pSW50

PAL4 in pJET1.2

this work

pSW52

4CL1 in pJET1.2

this work

pSW54

4CL1 in pACYCDuet-1

this work

pSW56

PAL1 and 4CL1 in pACYCDuet-1

this work

pSW57

PAL3 and 4CL1 in pACYCDuet-1

this work

pSW58

PAL4 and 4CL1 in pACYCDuet-1

this work

4.2.4 Dicinnamoylmethane production in E. coli
A typical fermentation procedure is as follows. Engineered E. coli BL21 (DE3)
strains were precultured overnight at 37 oC in 5 ml of LB medium supplemented with
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50 µg/ml kanamycin and 25 µg/ml chloramphenicol. The preculture was transferred
into 50 ml of LB medium with the same antibiotics and cultured at 37 oC until the
OD600 reached 0.4~0.6. IPTG was then added at a final concentration of 1 mM and the
induced culture was maintained at 25 oC with shaking at 250 rpm for an additional 5 h.
After that, 3 mM L-Phe, 40 g/l glucose and 25 g/l CaCO3 were added, and the culture
was incubated at 25 oC for an additional 60 h. The fermentation broth was harvested
by centrifugation at 4,000 rpm for 10 min. The supernatant was adjusted to pH 3.0
with 6 M HCl and extracted with an equal volume of ethyl acetate. The cells were
extracted with 10 ml of methanol by sonication. The extracts were concentrated by
solvent evaporation and subjected to product analysis.

4.2.5 Microplate-based assay for dicinnamoylmethane biosynthesis in E. coli
To purify 1 for structural characterization and quantification of its production in
the engineered E. coli strains, the extract of 100 ml of the fermentation broth of E.
coli BL21 (DE3)/pSW24+pSW56 was separated on a silica gel 60 open column. The
column was successively washed with a gradient of hexane/acetone (1:0, 9:1, 3:1, 1:1,
and 0:1, v/v). The fraction eluted by hexane/acetone (9:1) was found to contain 1 and
further separated on an Agilent 1200 HPLC using a SUPELOD SupelcosilTM
LC-PAH column (5 um, 250 mm × 10 mm), eluted with acetonitrile-water (70:30, v/v)
at a flow rate of 3 ml/min for 45 min. The peak at 30 min was collected, yielding 12
mg of 1 in pure form. The compound was structurally characterized based on its
ESI-MS and NMR data.
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Dicinnamoylmethane (1): yellow powder. 1H NMR (300 MHz, acetone-d6): 
7.71 (4H, d, J = 5.9 Hz, H-6, H-6', H-10, and H-10'), 7.70 (2H, d, J = 15.1 Hz, H-4
and H-4'), 7.44 (6H, m, H-7, H-7', H-8, H-8', H-9, and H-9'), 6.89 (2H, d, J = 15.8 Hz,
H-3 and H-3'), 6.14 (1H, s, H-1). 13C NMR (75 MHz, acetone-d6):  184.4 (C-2 and
C-2'), 141.2 (C-4 and C-4'), 136.1 (C-5 and C-5'), 131.1 (C-8 and C-8'), 129.9 (C-7,
C-7', C-9, and C-9'), 129.1 (C-6, C-6', C-10, and C-10'), 125.2 (C-3 and C-3'), 102.6
(C-1).

The purified compound was dissolved in methanol and prepared as different
concentrations by a serial dilution. The solutions of 1 was distributed into the wells in
a 96-well UV-plate (Corning, NY, USA) and measured on a SpectraMax® 190
Absorbance Plate Reader at 390 nm to get the standard curve. For time course
analysis, the fermentation broths were sampled at 12, 24, 36, 48, 60, and 72 h,
respectively. The samples (1 ml each) were extracted as described above and the dried
extracts were re-dissolved in 1 ml of methanol, from which 200 µl of each extract was
subjected to titer analysis on the SpectraMax® 190 Absorbance Plate Reader.

4.2.6 HPLC analysis of dicinnamoylmethane biosynthesis in E. coli
A standard curve of 1 was established by injecting different amounts of the
purified compound into HPLC and correlating the peak areas to the amounts.
Product analysis was conducted using an Agilent 1200 HPLC system with an Agilent
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Eclipse XDB-C18 column (5 um, 250 mm × 4.6 mm). The samples were eluted with
acetonitrile-water (70:30, v/v) at a flow rate of 1 ml/min for 30 min, and the product
was detected at 390 nm. For time course analysis, 200 µl of the same samples used for
the microplate-based assay were analyzed by HPLC.

4.2.7 Quantitative real-time PCR analysis of PAL expression in E. coli
For quantitative real time-PCR (qRT-PCR) analysis of the expression of PAL1,
PAL3 and PAL4, total RNA was extracted from E. coli BL21(DE3)/pSW24+pSW56,
E. coli BL21(DE3)/pSW24+pSW57 and E. coli BL21(DE3)/pSW24+pSW58,
respectively, using a Quick-RNA Miniprep kit (ZYMO Research, CA, USA). cDNAs
were then synthesized by RT-PCR with a SuperScript III First-Strand Synthesis
System (Invitrogen, CA, USA). The synthesized cDNAs served as the template for
qRT-PCR. Reactions were run using the iTaq Universal SYBR Green Supermix
(Bio-Rad, CA, USA) in 20-µl reaction mixtures on a Bio-Rad iQ5 Real Time PCR
Detection System (Bio-Rad, CA, USA). A pair of primers including PAL-RT-F and
PAL-RT-R (Table 3) was used. 16S rDNA was chosen as the internal control with
16S-RT-F and 16S-RT-R as the primers (Table 3). Initial denaturation was done at
95 °C for 30 s, followed by 40 cycles of 95 °C for 15 s and 60 °C for 30 s. Data were
analyzed with auto Ct (threshold cycle) and auto baseline functions of the system and
Ct values of the triplicate reactions were averaged. ΔCt were determined as Ct
(internal control) - CtPAL for each gene.
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4.2.8 Purification and structural analysis of the new fluorinated dicinnamoylmethane
derivative 2
The fermentation procedure was same as described above excepted that 3 mM
2-fluoro-L-Phe was added instead of L-Phe after induction by 1 mM IPTG for 5 h at
25 °C. The culture was incubated at 25 °C for an additional 60 h. The extract was
analyzed by LC-MS. For large-scale preparation of the new fluorinated
dicinnamoylmethane derivative 2, the fermentation was performed in 2 L of LB
medium. The extract was first separated on a silica gel 60 open column, successively
eluted with increasing concentrations of hexane/acetone (1:0, 9:1, 3:1, 1:1, and 0:1,
v/v). The fractions containing 2 were lumped and further separated on a SUPELOD
Supelcosil LC-PAH column (5 µm, 250 mm × 10 mm), eluted with acetonitrile-water
(70:30, v/v) at a flow rate of 3 ml/min for 45 min purification. The peak at 35 min was
collected and subjected to NMR analysis.

4.3 Results

4.3.1 Design of a reporter assay for PAL expression in E. coli
Dicinnamoylmethane (1) is a curcuminoid synthesized by the sequential actions
of PAL, 4CL and CUS (Fig. 15a). PAL catalyzes nonoxidative deamination of L-Phe
to yield trans-cinnamic acid, which is then ligated with CoA by 4CL to generate
cinnamoyl-CoA. CUS is a type III PKS and it takes two units of cinnamoyl-CoA and
one unit of malonyl-CoA to yield 1. We chose to use 1 as the reporter molecule for in
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vivo activity of PALs by taking advantage of its yellow color. To this end, we
designed a reporter assay system consisting of two plasmids that harbor 4CL and CUS,
respectively (Fig. 15b). Specifically, a 4CL from A. thaliana, named 4CL1, was
cloned into pET28a to yield pSW24, while CUS from O. sativa was inserted into
pACYCDuet-1 to afford pSW54. A candidate PAL gene can be ligated into pSW54
between PstI and NotI (or other available sites such as BamHI and EcoRI). All these
three biosynthetic genes in pET28a and pACYCDuet-1 are under the control of
separate T7 promoters. Co-expression of the resulting plasmids will build the
necessary enzymatic platform for dicinnamoylmethane biosynthesis. The production
of 1 will be visible because of its yellow color and the titer can be monitored by
HPLC or UV-Vis microplate reader.

Fig. 15 Design of a reporter assay for PALs. a. Biosynthetic pathway of 1 from L-Phe
by the sequential actions of PAL, 4CL and CUS. b. A reporter assay for screening of
PALs in E. coli. The system consists of two plasmids. The first one contains CUS and
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the second one has 4CL1. A candidate PAL gene will be ligated into the second vector
between PstI and NotI. Co-expression of the two plasmids will lead to the biosynthesis
of 1, which is visible for its yellow color and can be analyzed by HPLC or UV-Vis
microplate reader.

4.3.2 Examination of the expression of three PALs from red clover in E. coli using the
designed in vivo reporter assay
To test the effectiveness of the designed in vivo reporter assay, we chose three
plant PALs from T. pretense. The cDNAs encoding PAL1, PAL3 and PAL4 were
individually introduced to pSW54 between the PstI and NotI sites to yield pSW56,
pSW57 and pSW58 (Table 4), respectively. Color changes in the fermentation broths
of E. coli/pSW24+pSW56, E. coli/pSW24+pSW57 and E. coli/pSW24+pSW58 were
observed, compared to E. coli/pSW24+pSW54 that served as the negative control.
LC-MS analysis of the extracts of these cultures revealed that E. coli/pSW24+pSW56,
E. coli/pSW24+pSW57 and E. coli/pSW24+pSW58 produced the same yellow
product 1 at 17.5 min, as shown in Fig. 16a. The ion peaks [M+H]+ at m/z 277.0 and
[M+Na]+ at m/z 298.9 in the ESI-MS spectra suggested that 1 has a molecular weight
of 276. This peak showed a maximum UV absorption at 390 nm, which is consistent
with that for dicinnamoylmethane [26]. NMR analysis confirmed that the purified
compound is dicinnamoylmethane [26]. These results suggested that all three tested
PALs were functionally expressed in E. coli BL21 (DE3). We also found that more
than 71% of 1 was in the E. coli cells.
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Fig. 16 HPLC-MS analysis of the production of 1 in engineered E. coli.a. HPLC
traces of the methanol extract of the cell pellets of E. coli/pSW24+pSW54 (i), E.
coli/pSW24+pSW56 (ii), E. coli/pSW24+pSW57 (iii) and E. coli/pSW24+pSW58 (iv);
b. ESI-MS (+) spectrum of the peak at 17.5 min; c. UV absorption spectrum of the peak
at 17.5 min.

4.3.3 Development of a quantitative microplate-based assay for the production of 1
To differentiate the titers of 1 by different PALs, a microplate-based assay was
developed. Briefly, 1 ml of the fermentation broth was pelleted by centrifugation. The
supernatant was extracted with 1 ml of ethyl acetate and the cells were extracted with
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500 µl of methanol. The extracts were combined and dried under reduced pressure.
The sample was then re-dissolved in methanol, distributed into a 96-well UV-plate
and measured on a UV-Vis microplate reader at 390 nm. The concentrations were
determined based on the standard curve of 1 (Fig. 17a). Using this assay, we
conducted a time course analysis for E. coli/pSW24+pSW56, E. coli/pSW24+pSW57
and E. coli/pSW24+pSW58. After the addition of L-Phe, glucose and CaCO3, the
fermentation broths were sampled at 12, 24, 36, 48 60 and 72 h, and the titers of 1 are
shown in Fig. 17b. It is apparent that E. coli/pSW24+pSW56 produced much higher
amounts of 1 than E. coli/pSW24+pSW57 and E. coli/pSW24+pSW58 did, suggesting
that the overall performance (expression and efficiency) of PAL1 is better than the
other two PALs. The best titer of 1 by E. coli/pSW24+pSW56 that contains PAL1,
4CL1 and CUS reached 0.36 g/l after 72 h, while the titers by PAL3 and PAL4 were
only 0.08 g/l and 0.11 g/l, respectively. To validate the microplate-based assay, the
same samples were analyzed by HPLC (Fig. 17c) and the titers of 1 were determined
based on the areas of peak 1. Although there were occasional small differences
between the HPLC and microplate reader measurements, which was likely due to the
interfering compounds in the fermentation broth at different stages, overall the data
from the microplate-based assay and HPLC analysis were consistent, indicating that
this quantitative microplate-based assay was effective.
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Fig. 17 Time course analysis of the production of dicinnamoylmethane by the
co-expression of 4CL1 and CUS with PAL1, PAL3 or PAL4. a. Standard curve of
dicinnamoylmethane on a UV-Vis microplate reader at 390 nm; b. Time course
analysis by a UV-Vis microplate reader at 390 nm; c. Validation of the
microplate-based assay by HPLC analysis at 390 nm.

4.3.4 qRT-PCR analysis of the expression of PAL1, PAL3 and PAL4 in E. coli
We also used qRT-PCR to compare the expression level of the three plant PALs
in E. coli/pSW24+pSW56, E. coli/pSW24+pSW57 and E. coli/pSW24+pSW58,
respectively. As shown in Table 5, the qRT-PCR results indicated that the expression
level of PAL1 was higher than the other two, and the expression level of the PAL3
was the lowest among these three PALs. This is consistent with the analysis results of
the titers of 1 in the corresponding E. coli strains, although the latter is the combined
effects of both the expression level and catalytic activity of PALs.

72h
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Table 5. Relative expression level of three different plant PALs in E. coli
Enzyme

∆Ct

PAL1

-4.06±0.46

PAL3

-1.10±0.34

PAL4

-3.50±0.36

4.3.5 Precursor-directed biosynthesis of a new fluorinated dicinnamoylmethane
derivative
With the designed reporter assay, we determined that PAL1 showed the best
performance in E. coli among the three tested plant PALs. We then used the strain E.
coli/pSW24+pSW56 that expressed PAL1, 4CL1 and CUS for the synthesis of new
curcuminoids. Previous studies have shown that it is possible to synthesize new
curcuminoids with the curcuminoids biosynthetic enzymes by feeding different
precursors [27, 28]. To this end, we fed 2-fluoro-L-Phe into the induced culture of E.
coli/pSW24+pSW56 instead of L-Phe. As shown in Fig. 18a, LC-MS analysis
revealed that three major curcuminoids were produced. In addition to 1, two new
products 2 and 3 were synthesized. The ESI-MS spectra of 2 (Fig. 18b) revealed that
it has a molecular weight of 294, suggesting that it is a monofluorinated derivative of
1. The ESI-MS spectra of 3 (Fig. 18c) showed that this compound has a molecular
weight of 312, suggesting that it has one more fluorine atom than 2 and is a
difluorinated derivative of 1. While 6, 6'-difluoro-dicinnamoylmethane has been
previously reported [27],

13

C NMR spectrum of 2 revealed that it has a quaternary

carbon at C-6 instead of a CH in 1. The chemical shift of C-6 is 163.3, suggesting
that this position is fluorinated. Further 1D and 2D NMR analysis confirmed that it is
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6-fluoro-dicinnamoylmethane, which is a new compound. The proton and carbon
signals are given in Appendix D. These two fluorinated products resulted from the
incorporation of one and two 2-fluoro-L-Phe units, respectively.

Fig. 18 LC-MS analysis of the production of a new fluorinated dicinnamoylmethane
derivative 2 in E. coli.a. HPLC trace of the methanol extract of the cells of E.
coli/pSW24+pSW56 supplemented with 2-fluoro-L-Phe; b. ESI-MS (+) spectrum of 2;
c. ESI-MS (+) spectrum of 3.

4.4 Conclusion
PAL is a key enzyme involved in both primary and secondary metabolism, and
has attracted more and more attention because of their applications in agriculture,
medicine and industry. The efficiency of PAL has direct impacts on the efficacy of
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the enzyme-based treatment or an industrial production process. Screening of efficient
PALs is thus of significant interest. In this work, we developed a microplate-based
reporter assay for screening of efficient PALs using the E. coli system, which is easily
accessible. PAL is involved in the biosynthesis of many plant phenylpropanoids,
among which curcuminoids are a group of yellow compounds synthesized from L-Phe
by a type III polyketide biosynthetic pathway consisting of three enzymes. In this
work, we developed a novel reporter assay for PALs using a two-plasmid screening
system that expresses 4CL1 from A. thaliana and CUS from O. sativa. Together with
any functional PAL, this system will yield 1, which allows efficient and visible
screening of PALs in E. coli. Further development of the microplate-based assay,
which was validated by HPLC analysis, will facilitate high throughput screening for
efficient PALs.

Biological reporter systems have been developed for different uses in research
and industry. For example, a reporter assay has recently been developed for bacterial
and mammalian cells based on the blue color of the non-ribosomal peptide
indigoidine. Indigoidine is synthesized from two units of L-glutamine [29].
Accordingly, the designed system consisted of the Streptomyces lavendulae
non-ribosomal

peptide

synthetase

BpsA

and

the

Streptomyces

verticillus

4'-phosphopantetheinyl transferase Svp that activates the thiolation domain in BpsA
[30]. While our work established a reporter assay in E. coli, it is possible to construct
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similar screening system in other hosts such as yeasts and mammalian cells for
different purposes with the help of synthetic biology techniques.

The tested three PALs were from red clover (T. pratense). PAL3 and PAL4 are
nearly identical with 97% identity, and they share only 89% identity with PAL1.
These enzymes are involved in the biosynthesis of phenylpropanoid compounds in the
plant, and PAL3 and PAL4 were also reported to participate in pathogen defense
response [31]. However, no biochemical studies on these enzymes have been
performed and their catalytic activities remain unknown. We compared these three
PALs in E. coli using the designed reporter assay and found that PAL1 showed the
best overall performance, which is a combined effect of the expression level and
catalytic efficiency. Furthermore, the qRT-PCR analysis confirmed that the
expression level of PAL1 was the highest in E. coli among the three tested PALs. It is
known that many molecular technology tools, such as RT-PCR, SDS-PAGE and
western blotting, can be used to analyze protein expression at the transcriptional or
translational level. However, these analyses are often time-consuming and more
costly. The reporter assay we established provides a novel, visible and easy-to-assay
approach for screening highly efficient PALs, which requires remarkably smaller
volumes, lower costs and shorter time compared to traditional analytic methods.
Furthermore, the results from this assay directly reveal the overall performance of
PALs in E. coli instead of only reporting the expression level or catalytic efficiency.
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With the successful screening of the most efficient enzyme from a group of plant
PALs, this reporter assay can be further utilized to screen more efficient PALs from a
larger library for the production of useful products. In this work, the titer of 1 reached
0.36 g/l in E. coli. Because more than 71% of the product is in the cells, the screening
can be further simplified by focusing on the cells and discarding the supernatants after
centrifugation. Precursor-directed biosynthesis of 2 and 3 revealed that PAL1 can
deaminate 2-fluoro-L-Phe to yield the corresponding fluorinated trans-cinnamic acid,
which is then processed by 4CL1 and CUS to generate the fluorinated curcuminoids.
This confirmed that the three biosynthetic enzymes including PAL1, 4CL1 and CUS
have relatively flexible substrate specificity, thus opening an opportunity to
synthesize novel curcuminoids by feeding different precursors.
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CHAPTER 5 BIOSYNTHESIS AND ANTIBACTERIAL ACTIVITY OF
DUTOMYCIN AND ANALOGS

ABSTRACT
Dutomycin, an anthracycline natural product, was isolated with its precursor
POK-MD1 from Streptomyces minoensis NRRL B-5482. A putative dutomycin
biosynthetic gene cluster was discovered by genome sequencing and its involvement
in dutomycin biosynthesis was confirmed by disruption of the ketosynthase gene. The
open reading frames were analyzed and annotated based on the sequence homology.
Two polyketide synthases (PKSs) are present in the gene cluster, including a type II
PKS and an iterative type I PKS. The minimal type II PKS (DutA, DutB and DutC)
synthesizes the nascent poly-β-ketone chain, which is subjected to extensive
modifications by tailoring enzymes such as oxygenases, methyltransferases and
glycosyltransferases to afford POK-MD1. The type I PKS DuG repeatedly uses its
active sites to create a 9-carbon triketide chain that is subsequently transferred to the
second sugar moiety at 4"-OH of POK-MD1 to yield dutomycin. Using a
heterologous recombination approach, we disrupted four genes including two
methyltransferases (dutMT1 and dutMT2) and two glycosyltransferases (dutGT1 and
dutGT2). Analysis of the metabolites of these mutants revealed the functions of these
genes and yielded three new dutomycin analogs SW140, SW82 and SW75.
Dutomycin, POK-MD1, SW82 and SW75 were subjected to the antibacterial assay.
Dutomycin and its C6-demethyled derivative SW82 showed strong antimicrobial
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activity

against

Gram-positive

bacteria

Staphylococcus

aureus

(SA)

and

methicillin-resistant S. aureus (MRSA). In contrast, POK-MD1 and SW75 have no
activities at test concentrations up to 250 g/ml, indicating the essential role of the
9-carbon polyketide chain attached to 4"-OH. While the MICs of dutomycin against
SA and MRSA were determined to be 0.25 µg/ml, it is interesting that SW82 has
stronger activity with the MICs 0.125 µg/ml against the same strains, indicating that
the antibacterial activity of these molecules can be improved by biosynthetic
structural modifications.

5.1 Introduction
Antibiotics play a critical role in treating bacterial infections and have saved
millions of lives. The first antibiotic was discovered in 1928, and since then, more
natural compounds with promising antibacterial activities have been identified and
used as anti-infectious drugs such as tetracycline and kanamycin. However, extensive
uses of antibiotics also led to the emergence of drug resistance. For example,
methicillin-resistant Staphylococcus aureus (MRSA) is considered a "superbug"
because its ability to fight off treatment, including the antibiotic methicillin. Spread of
these antibiotic-resistant bacterial pathogens poses a serious threat to public health.
Therefore, there is an urgent need for new generation antibiotics that can directly
combat MRSA and other pathogenic bacteria.
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Natural products are an important source of new drugs. In fact, many clinically
used antibiotics are natural products including tetracycline, penicillin, and
vancomycin. Actinomycetes are a major group of producers of many antibiotics.
Continuous search for new antimicrobial molecules from nature is critical for
development of new antibiotics. On the other hand, engineered biosynthesis can
complement the time-consuming and resource-intensive discovery process, and
represents an attractive approach to creating molecular diversity for drug discovery.
Novel “unnatural” natural products can be obtained through direct genetic
modification of the biosynthetic pathway in the producing strains or combinatorial
biosynthesis in a heterologous host. Polyketides are a large group of medicinally
important

natural

products,

exemplified

by

lovastatin

(anti-cholesterol),

oxytetracycline (antibacterial), pradimicin A (antifungal and antiviral), and
erythromycin (antibacterial). These molecules are assembled by polyketide synthases
(PKSs) and associated tailoring enzymes through stepwise condensations of simple
carboxylic acid precursors and further structural decorations [1]. PKSs are classified
into three types. Type I PKSs such as DEBS involved in erythromycin biosynthesis
are modular enzymes that contain a series of catalytic domains [2]. Ketosynthase (KS),
acyl transferase (AT) and acyl carrier protein (ACP) are essential domains for
polyketide chain elongation. Reductive domains such as ketoreductase (KR),
dehydratase (DH) and enoyl reductase (ER) are also often found in type I PKSs. Type
II PKSs are discrete small enzymes that form multi-enzyme complexes to synthesize
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the polyketide structures. KS, chain length factor and ACP are the minimal PKS to
form the nascent poly-β-ketone chain, which is subjected to the modifications by
tailoring enzymes such as KR, aromatase (ARO), cyclase (CYC), oxygenase,
methyltransferase (MT) and glycosyltransferase (GT) to form diverse aromatic
molecules [3]. Type III PKSs are single enzymes that form a dimeric structure to
catalyze substrate loading, chain elongation, and cyclization [4]. PKSs are one of the
most amenable systems for engineered biosynthesis because of their inherent genetic
organization and ability to produce structurally and functionally diverse molecules
[5].

Here, we report the isolation and identification of the anthracycline antibiotic
dutomycin (4, Fig.19) and its precursor POK-MD1 (5, Fig.19) from Streptomyces
minoensis NRRL B-5482. The dutomycin biosynthetic gene cluster was then
discovered by genome sequencing and confirmed by disrupting the ketosynthase gene.
Functions of several tailoring enzymes were identified by targeted gene disruption
and three new dutomycin analogs (6-8, Fig.19) were generated. Compounds 4-7 were
tested for their antibacterial activity and 6 was found to have better activity against
SA and MRSA than the natural product 4. This work not only provides useful
information about the formation of dutomycin and the structure-activity relationship
(SAR), but also yields a potent antibacterial agent for further structure and activity
optimization.

86
6"

OR2

O

4"

1"
1'

13

O

16

H3CO

R1
1a

2
1

12a
12

11a
6

4
4a

O

11

O
OH

5 5a

OH O

5' 6'

O

O

O

7"

3"

OH

O
OH

H3CO

O

OH

OH

4'
9

10
6a
7

OH
O

OH
O

14

OH O

OH
O

O

15

O

6"'

SW75 (7)

7"'
9"'

O
2"'

5"'

O

4"'

Dutomycin (4) R1 = CH3, R2 =

OH
OH

H3CO

1"'

OH

3"'

POK-MD1 (5) R1 = CH3, R2 = H

6"'

O

OH O

OH
O

O

9"'

O
2"'

SW82 (6) R1 = H, R2 =

7"'
5"'
4"'

1"'

SW140 (8)

Fig. 19 Structures of dutomycin (4) and analogs 5-8.

5.2 Materials and methods

5.2.1 General Equipment.
Products were analyzed and purified on an Agilent 1200 HPLC instrument with
an Agilent Eclipse XDB-C18 column (5 μm, 250 × 4.6 mm). The samples were eluted
with acetonitrile-water (30:70, v/v to 95:5, v/v) at a flow rate of 1 ml/min for 30 min
and detected at 460 nm. ESI-MS spectra were obtained on an Agilent 6130
quadrupole LC-MS in the negative mode. 1D and 2D NMR spectra were recorded on
a JEOL ECX-300 NMR instrument (300 MHz for 1H NMR and 75 MHz for

13

C

NMR). The chemical shift (δ) values are given in parts per million (ppm). The
coupling constants (J values) are reported in hertz (Hz).

5.2.2 Strains and Vectors.
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S. minoensis NRRL B-5482 was obtained from the USDA Agricultural Research
Service Culture Collection. E. coli ATCC 25922, S. aureus ATCC 25923 and
methicillin-resistant S. aureus ATCC 33591 were purchased from the American Type
Culture Center and used for the antibacterial assay.

E. coli XL-1 Blue (Stratagene)

and the pJET1.2 cloning vector (Fermentas) were used for routine subcloning. E. coli
ET12567 (pUZ8002) and pKC1139 vector were used for the gene disruption
experiments [20].

5.2.3 Media and Culture Conditions.
S. minoensis NRRL B-5482 and its mutants were maintained on YM (yeast
extract-malt extract) agar plate at 28oC [21]. S. aureus and E. coli were cultured in
Luria-Bertani (LB) broth at 37oC. MS [21], ISP4, and TSB media were used in the
conjugation. Ampicillin (50µg/ml) and apramycin (50µg/ml) were added to the media
appropriately for the cloning and conjugation.

5.2.4 Extraction and Sequencing of the Genomic DNA.
S. minoensis NRRL B-5482 was grow in 50 ml of YM medium at 28oC with
shaking at 250 rpm for 5 days. The genomic DNA was extracted as previously
reported. The genome was then sequenced using an Illumina MiSeq desktop
sequencer and assembled with the short read de novo assembler Velvet. The genome
sequence was analyzed with RAST (rapid annotation using subsystem technology).
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The dutomycin gene cluster was deposited in GenBank under accession number
KP710956.

5.2.5 Construction of Plasmids.
To disrupt three different ks fragments, dutMT1, dutMT2, dutGT2 and dutGT1 in
S. minoensis, a homologous recombination single crossover approach was used. To
find the type II KS involved in dutomycin biosynthesis, a ~0.6-kb fragment was
amplified from the genomic DNA of S. minoensis using a pair of degenerated primers
(KSα-F

and KSα-R, Table S1) with a 30-cycle PCR program (15 s at 98oC, 15 s at

55oC, and 30 s at 72oC). The PCR product was ligated into pJET1.2 vector to yield
pLS51, pLS52 and pLS53 based on the sequencing results. The three different ks
fragments in these plasmids were then excised and ligated into pKC1139 between
BglII and BamHI to afforded pLS54, pLS55 and pLS56, respectively.

For

inactivation of dutMT1, dutMT2, dutGT2 and dutGT1, 0.6-kb fragments of these
genes

were

amplified

DutMT1-F/DutMT1-R,

from

the

genomic

DutMT2-F/DutMT2-R,

DNA

with

primer

paris

DutGT2-F/DutGT2-R,

and

DutGT1-F/DutGT1-R (Appendix E) using a 30-cycle PCR program (15 s at 98oC, 15
s at 60oC, and 30 s at 72oC) and ligated to pJET1.2 to yield pSW70, pSW82, pSW83
and pSW138, respectively. After the sequences were confirmation by sequencing,
these gene fragments were introduced to pKC1139 to form pSW75, pSW85, pSW91
and pSW140 between HindIII and XbaI. All the plasmids used in this study are listed
in Table 6.
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Table 6. Plasmids used in Chapter 5.
Plasmid
pLS51
pLS52
pLS53
pLS54
pLS55
pLS56
pSW70
pSW75
pSW82
pSW83
pSW85
pSW91
pSW138
pSW140

Description
ks1 in pJET1.2
ks2 in pJET1.2
ks3 in pJET1.2
ks1 in pKC1139
ks2 in pKC1139
ks3 in pKC1139
dutGT2 fragment in pJET1.2
dutGT2 fragment in pKC1139
dutMT1 fragment in pJET1.2
dutMT2 fragment in pJET1.2
dutMT2 fragment in pKC1139
dutMT1 fragment in pKC1139
DutGT1 fragment in pJET1.2
DutGT1 fragment in pKC1139

Reference
this work
this work
this work
this work
this work
this work
this work
this work
this work
this work
this work
this work
this work
this work

5.2.6 Conjugation and Confirmation of the Mutants.
The gene disruption plasmids were introduced to E. coli ET12567 (pUZ8002)
through chemical transformation. Plasmids were introduced into S. minoensis NRRL
B-5482 by E. coli–Streptomyces conjugation, following the procedure as reported [22,
23]. The resulting E. coli strains were used as donors and S. minoensis NRRL B-5482
was the acceptor. The positive colonies were picked to TSB medium with 50 µg/ml of
apramycin after 20 days of culture on MS plates. The colonies were grown in TSB
medium at 28o C for 5 days and 50 µl of these cultures were spread on ISP4 plates
with 50 µg/ml of apramycin. Colonies showing up at 37oC were considered as
asrecombination strains, which were further cultured on YM plate with the 50 µg/ml
of apramycin at 28oC for product checking. The mutants were confirmed by PCR
analysis using genome- and pKC1139-specific primers (Appendix E) and a 30-cycle
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PCR program (30 s at 98oC, 30 s at 58oC, and 60 s at 72oC). The PCR verification
results are shown in Appendix E.

5.2.7 Extraction, Analysis and Purification of Compounds.
S. minoensis NRRL B-5482 and its knockout mutants were grown on YM agar
plates (with or without apramycin). The cultures were extracted three times with an
equal volume of ethyl acetate. The extracts were then dried under reduced pressure
and re-dissolved in methanol for LC-MS analysis. To isolate compounds 4 and 5, 1 l
of culture of wild type S. minoensis NRRL B-5482 was extracted and subjected to
silica gel 60 column chromatography, eluted with 100:0, 75:25, 50:50, 25:75, 0:100 %
CHCl3-MeOH (v/v) to yield 5 fractions. The fraction (75:25) was found to contain 4.
It was further separated by HPLC with an Agilent Eclipse XDB-C18 column (5 μm,
250 × 4.6 mm) and eluted with a gradient of acetonitrile-water (70:30, v/v to 75:25,
v/v in 20 min) at 1 ml/min. The peak at 17 min was collected to yield 48.7 mg of 4 in
pure form. Similarly, the fraction (50:50) containing 5 was separated by the same
HPLC instrument, eluted with acetonitrile-water from 30:70, v/v to 35:65, v/v in 15
min at 1 ml/min, to yield 6.2 mg of 5. A total of 38.9 mg of 6 was isolated from 1 l of
S. minoensis-ΔMT1 culture using the same procedure as for 4. For the purification of
7, the extract of 1 l of S. minoensis-ΔGT2 culture was separated on a MCI column,
eluted with 0:100, 25:75, 50:50, 75:25, 100:0% MeOH-H2O (v/v) to yield 5 fractions.
The 100% MeOH fraction was found to contain 7 which was further separated by
HPLC using an Agilent Eclipse XDB-C18 column (5 μm, 250 × 4.6 mm). The sample
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was eluted with acetonitrile-water 30:70 (v/v) at 1 ml/min for 15 min, and the peak at
12 min was collected to yield 15.4 mg of 7 in pure form. All these compounds were
subjected to NMR and MS analyses. The major product 8 in S. minoensis-ΔDutGT1
was identified by MS and a comparison with the methanolysis product of 4.

5.2.8 Minimum inhibition concentration test.
E. coli XL-1 Blue, S. aureus ATCC 25923 and methicillin-resistant S. aureus
ATCC 33591 were incubated in LB broth with the test samples at different
concentrations (64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, and 0.064 µg/ml) at 37°C in
96-well plates, and the growth was analyzed after 20 hours to determine the MICs.

5.3 Results

5.3.1 Isolation and Identification of Two Anthracyclines from S. minoensis NRRL
B-5482.
HPLC analysis of the ethyl acetate extract of the culture of S. minoensis NRRL
B-5482 on YM agar at 460 nm showed a major product at 25.6 min (4) and a minor
metabolite at 10.4 min (5), respectively (trace i, Fig. 20). Both compounds shared the
typical UV absorptions of anthracycline antibiotics (Appendix E), suggesting that
they might be structurally related analogs. ESI-MS spectrum of 4 showed the [M-H]ion peak at m/z 854.2 (Appendix E), suggesting that it has a molecular weight of 854,
which is the same as dutomycin, an anticancer agent previously isolated from
Streptomyces sp. 1725. The 1H and

13

C NMR data are consistent with the reported
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data, which confirmed that 4 is dutomycin (Fig. 19). ESI-MS analysis revealed that
the molecular weight of 5 is 716 based on the [M-H]- peak at m/z 715.1 (Fig. S2),
suggesting that 5 is a dutomycin derivative that lacks the C-4" side chain. This
compound

was

previously

found

in

the

ΔpokMT1

mutant

of

the

polyketomycin-producing strain Streptomyces diastatochromogenes Tü6028, and was
named POK-MD1. However, this compound was not structurally characterized. Thus,
5 was subjected to a complete NMR analysis. The 13C NMR spectrum of 5 showed 35
carbon signals, which are 9 carbons than 4. A comparison of the spectra with those of
4 revealed that the carbon signals of the 9-carbon side chain at C-4" were missing.
Accordingly, 5 was characterized as POK-MD1 shown in Fig. 19. The 1H and

13

C

NMR signals were assigned and are shown in Tables 7 and 8, respectively.
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Fig. 20 HPLC analysis of the metabolites of wide type (WT) S. minoensis
NRRL-B5482 and S. minoensis NRRL-B5482/pLS54 mutant at 460 nm.
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Table 7. 13C NMR data (75 MHz) for 4-7 (4 and 6 in CDCl3, 5 in CD3OD, and 7 in
DMSO-d6).
Position
1a
1
2
3
4
4a
5
5a
6
6a
7
8
9
10
11a
11
12a
12
13
14
15
16
1'
2'
3'
4'
5'
6'
1''
2''
3''
4''
5''
6''
7''
1'''
2'''
3'''
4'''
5'''
6'''
7'''
8'''

4
132.9
181.5
161.3
108.8
190.4
113.8
162.5
123.5
192.6
81.2
195.2
110.8
191.2
73.9
75.7
35.0
150.9
132.4
16.8
200.9
26.7
57.1
102.2
29.5
30.3
80.1
74.5
17.4
100.3
37.0
68.9
74.2
62.8
16.8
25.9
167.4
125.2
21.1
150.1
33.5
20.7
39.8
20.8

5
133.9
182.8
162.7
109.6
189.5
114.9
163.3
124.5
192.2
83.4
195.3
112.6
192.2
73.2
75.6
35.5
152.8
133.8
17.0
200.5
27.7
57.7
103.5
30.6
31.3
81.3
74.7
17.9
101.3
37.1
70.6
75.2
64.5
17.2
27.0

6
133.9
179.1
160.7
110.6
189.8
113.6
163.7
123.3
190.5
81.5
195.4
110.7
191.7
73.5
75.7
36.8
150.1
120.1
201.3
25.9
57.1
102.2
29.5
30.3
80.1
74.6
18.1
100.4
37.1
69.0
74.2
62.9
16.8
25.9
167.5
125.3
21.1
150.1
33.5
20.8
39.8
20.9

7
132.0
181.0
161.7
108.4
190.7
111.3
160.6
123.2
193.5
82.2
196.5
112.8
191.5
74.4
75.8
34.1
151.0
131.5
16.1
198.5
26.3
57.1
101.5
30.2
30.7
70.2
75.2
16.9
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9'''

14.4

14.4

Table 8. 1H NMR data (300 MHz) for 4-7 (4 and 6 in CDCl3, 5 in CD3OD, and 7 in
DMSO-d6).
Position

4

5

6

7

3
5-OH
10
11

6.11 (1H, s)
14.17 (1H, s)
4.43 (1H, brs)
3.78 (1H, d, 17.5)
3.01 (1H, m)
2.57 (3H, s)
2.70 (3H, s)
3.93 (3H, s)
4.66 (1H, d, 8.2)
1.57 (1H, m)
2.18 (1H, m)
2.11 (1H, m)
1.63 (1H, m)
3.11 (1H, m)
3.02 (1H, m)
0.58 (3H, d, 5.5)
4.97 (1H, d, 3.1)
1.88 (1H, m)
1.60 (1H, m)
4.76 (1H, s)
4.38 (1H, q, 6.5)
1.07 (3H, d, 6.9)
1.07 (3H, s)
1.91 (3h, s)
5.70 (1H, dd, 1.0,
11.3)
3.07 (1H, m)
0.96 (3H, d, 6.5)
1.25 (2H, m)
1.25 (2H, m)
0.86 (3H, t, 6.5)

6.26 (1H, s)
4.46 (1H, brs)
3.78 (1H, d, 17.5)
3.03 (1H, m)
2.60 (3H, s)
2.65 (3H, s)
3.93 (3H, s)
4.67 (1H, brs)
1.57 (1H, m)
2.12 (1H, m)
2.12 (1H, m)
1.61 (1H, m)
3.10 (1H, m)
2.95 (1H, m)
0.56 (3H, m)
4.95 (overlapped)
1.85 (1H, m)
1.60 (1H, m)
4.86 (overlapped)
4.30 (1H, q, 6.3)
1.19 (3H, d, 6.9)
1.14 (3H, s)

6.17 (1H, s)
13.50(1H, s)
4.46 (1H, brs)
3.75 (1H, d, 17.5)
3.05 (1H, m)
7.53 (1H, s)
2.70 (3H, s)
3.95 (3H, s)
4.71 (1H, d, 8.2)
1.56 (1H, m)
2.18 (1H, m)
2.12 (1H, m)
1.66 (1H, m)
3.13 (1H, m)
3.04 (1H, m)
0.68 (3H, d, 5.5)
4.99 (1H, d, 2.3)
1.86 (1H, m)
1.60 (1H, m)
4.76 (1H, s)
4.38 (1H, q, 6.5)
1.07 (3H, d, 6.9)
1.08 (3H, s)
1.92 (3H, s)
5.71 (1H, d, 10.3)

6.36 (1H, s)
14.10 (1H, s)
4.24 (1H, brs)
3.58 (1H, d, 17.5)
2.95 (1H, d, 17.8)
2.48 (3H, s)
2.58 (3H, s)
3.90 (3H, s)
4.52 (1H, d, 8.2)
1.45 (1H, m)
1.90 (1H, m)
1.90 (1H, m)
1.25 (1H, m)
2.83 (1H, brs)
2.83 (1H, brs)
0.42 (3H, d, 4.5)

12
13
15
16
1'
2'
3'
4'
5'
6'
1''
2''
4''
5''
6''
7''
3'''
4'''
5'''
6'''
7'''
8'''
9'''

3.10 (1H, m)
0.97 (3H, d, 6.6)
1.26 (2H, m)
1.26 (2H, m)
0.87 (3H, t, 6.5)

4 and 5 are two anthracyclines that feature a tetracyclic quinone core structure
and two sugar moieties, β-D-amicetose and α-L-axenose. The structures of 4 and 5
differ in the C-4" side chain. We proposed that 5 serves as a biosynthetic intermediate
in dutomycin biosynthesis. A time course analysis of the production of 4 and 5 was
conducted (Appendix E). The titer of 5 reached the highest (10.0±0.7 mg/l) at 4 days
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and then decreased with longer culture time, while the production of 4 kept increasing
over the time. After 10 days, the production of 5 cannot be detected. This observation
supports that 5 is a precursor of 4. The titer of 4 reached 82.5±1.8 mg/l at 10 days.

5.3.2 Identification of a Ketosynthase Gene Involved in Dutomycin Biosynthesis.
The structures of 4 and 5 indicated that they are synthesized through a type II
polyketide biosynthetic pathway. We used a pair of degenerated primers, KSα-F
(5'-TSGCSTGCTTCGAYGCSATC-3') and KSα-R (5'-TGGAANCCGCCGAABCC
GCT-3') [6] to amplify the KS gene fragment from the genome of S. minoensis NRRL
B-5482. These primers were used to amplify the conserved region of KS genes. A
0.6-kb fragment was obtained and ligated to pJET1.2. Sequencing of ten correct
clones revealed three different KS genes that are homologous to reported KS genes in
GenBank. These genes were named ks1, ks2 and ks3, indicating that there are multiple
type II polyketide biosynthetic gene clusters in this strain. To identify which ks gene
is involved in dutomycin biosynthesis, we ligated these three fragments into
temperature-sensitive E. coli-Streptomyces shuttle vector pKC1139 to yield the
corresponding plasmids pLS54, pLS55 and pLS56 (Table 6). These plasmids were
transferred into S. minoensis NRRL B-5482 through conjugation. Analysis of the
products of the mutants revealed that the production of 4 and 5 was abolished in S.
minoensis NRRL B-5482/pLS54 (trace ii, Fig.20), while the other two mutants still
produced the two compounds (data not shown). Thus, ks1 was identified to be
involved in dutomycin biosynthesis.
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5.3.3 Genome Sequencing and Discovery of the Dutomycin Biosynthetic Gene
Cluster.
To locate the dutomycin (dut) biosynthetic gene cluster and better understand this
strain, the genomic DNA of S. minoensis NRRL B-5482 was extracted and sequenced,
yielding approximately 10.4 Mb of sequence data (GC content of 70.1%). We then
searched the sequencing data using ks1 that was found to be involved in dutomycin
biosynthesis. A gene cluster covering 47.5-kb regions, which has 39 open reading
frames (ORFs) (Fig. 21A), were identified. It was deposited into GenBank under
accession number KP710956. Based on sequence homology search through BLAST,
the putative functions of these ORFs are given in Table 4. Many of the genes are
homologous to the previously reported polyketomycin biosynthetic genes. Based on
the putative functions of these genes, a dutomycin biosynthetic pathway is proposed
in Fig. 21B.

a
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Fig. 21 The biosynthetic gene cluster of dutomycin (dut) (A) and the proposed
biosynthetic pathway (B).

DutA, B and C are the KS, CLF, and ACP, respectively. They form the minimal
PKS that generates the nascent poly-β-ketone chain from 10 units of malonyl-CoA.
The ks1 fragment amplified for the gene disruption above is a part of dutA. Specific
primers including DutA-Check1 and DutA-Check2 were then designed (Appendix E).
Together with the vector-specific primers M13-47 and RM-V, the disruption of ks1
gene in S. minoensis NRRL B-5482/pLS54 was confirmed by PCR (Appendix E),
further supporting that ks1/dutA is involved in dutomycin biosynthesis.

The dut biosynthetic gene cluster contains a variety of tailoring enzymes. The
decaketide chain synthesized by the dut minimal PKS was then cyclized by the
immediate tailoring enzymes including DutD (aromatase), DutE (cyclase) and DutF
(cyclase) to form the tetracyclic structure.

Further decorations are done by
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additional tailoring enzymes such as oxygenases (DutO1-O4) and methyltransferases
(DutMT1 and DutMT2) to afford the aglycone 8. Nine deoxysugar biosynthetic genes
were found in the dut gene cluster and named dutS1-S9. These genes are proposed to
synthesize

the

two

NDP-deoxysugars,

including

NDP-D-amicetose

and

NDP-L-axenose from glucose-1-phosphate [7]. Two GTs, DutGT1 and DutGT2, then
transfer the sugar moieties to 10-OH of 8 to 5. DutG is an iterative highly reducing
type I PKS. It consists of six domains, including KS, AT, DH, ER, KR and ACP.
Analysis of the sequence of the AT domain showed the GHSXG motif. The previous
research reported that “X” in malonyl-specific ATs is usually a branched hydrophobic
amino acid such as valine (V) or isoleucine (I), while ATs that have a less bulky
residue such as glutamine (Q) or methionine (M) at this position select other
substrates including methylmalonate [2, 8, 9] . DutG-AT has a GHSMG motif,
suggesting that it selects a substrate other than malonyl-CoA. Based on the structure
of C-4" side chain of 4, it is apparent that the AT should takes malonyl-CoA as the
substrate. This was confirmed by the presence of the motif of VASH. It has been
previously reported that a conserved [YVW] ASH motif is present in
methylmalonyl-specific

ATs,

while

a

[HTVY]

AFH

motif

is

found

in

malonyl-specific ATs [10] . DutG selectively and repeatedly uses its reduction
domains to generate a triketide chain from three units of methylmalonyl-CoA. An
ACP shuttle-type acyltransferase (DutH) then transfers the triketide chain to the
10-OH of 5 to yield the final structure of 4. Two SARP family regulator genes are
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found in the dut gene cluster, dutK and dutV. The gene cluster also contains two ABC
transporter genes dutT and dutU, which are likely involved in transporting the final
product out of the cells.

5.3.4 Inactivation of Two Putative MTs (DutMT1 and DutMT2) Involved in
Decorating the Aglycone and Isolation of a New Demethylated Derivative of
Dutomycin.
DutMT1 and DutMT2 are two MTs that are supposed to be involved in the
synthesis of the aglycone 8. To understand their roles in dutomycin biosynthesis and
create new analogs, we disrupted these two genes in S. minoensis NRRL B-5482
using the same approach for ks1-ks3 described above. To this end, a fragment of
dutMT1 or dutMT2 was amplified and ligated to pKC1139 to yield the corresponding
disruption plasmid pSW91 and pSW85, respectively. Integration of pSW91 into the
genome of S. minoensis NRRL B-5482 was screened by the apramycin resistance. An
apramycin-resistant mutant was subjected to PCR analysis. As shown in Appendix E,
~1.0 kb gene fragments were amplified from the mutant using primer pairs
M13-47/DutMT1-Check1 (lane 3) and RM-V/DutMT1-Check2 (lane 4), while no
products were obtained from the wild type using the same primers. This result
confirmed that pSW91 successfully inserted into dutMT1 to yield the desired
ΔDutMT1 mutant. The products of this mutant were analyzed by LC-MS. As shown
in Fig. 22, the production of 4 in S. minoensis NRRL B-5482-ΔDutMT1 was not
detected, while a major product 6 at 26.8 min was produced. We then isolated 6 from
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a scaled-up culture of this mutant for structural characterization. ESI-MS analysis
revealed that the molecular weight of 6 is 840 according to the [M-H]- ion peak at m/z
839.1 (Fig. S2), which is 14 mass units smaller than 4. The

13

C NMR spectrum of 6

showed 43 carbons, one carbon less than 4. A comparison of the NMR spectra of 4
and 6 confirmed that a methyl group was missing in 6, while a new aromatic proton
signal was found. The only methyl group attached to an aromatic ring is 13-CH3.
Therefore, 4 is likely the 12-demethylated derivative of 4. This was supported by the
HMBC correlations of 12-H at δ 7.53 to C-1 (δ 179.1), C-11 (δ 36.8), C-4a (δ 113.6)
and C-5a (δ 123.3) (Fig. 24). Thus, the structure of 6 was determined to be
12-demethyldutomycin. It is a new compound and named as SW91. The carbon and
proton signals were assigned based on 2D NMR and a comparison with 4, and are
shown in Tables 7 and 8, respectively. The titer of 6 was determined to be 66.697±1.0
mg/l. Identification of 6 revealed that DutMT1 is a C-MT that attaches a methyl group
to C-12.

The

disruption

plasmid

pSW85

was

also

introduced

into

the

dutomycin-producing strain for single crossover to yield S. minoensis NRRL
B-5482-ΔDutMT2. The correct mutant was confirmed by PCR analysis (Appendix E).
Sequence analysis predicted that DutMT2 is a putative O-MT. However, HPLC
analysis of the products of S. minoensis NRRL B-5482-ΔDutMT2 revealed that this
mutant did not produce any anthracycline metabolites including 4 at all (trace not
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shown), suggesting that disruption of DutMT2 has shut down the entire dut
biosynthetic pathway. A similar phenomenon was observed in the previous study on
the polyketomycin biosynthetic gene cluster, where disruption of PokMT3 also
abolished

the

production

of

any

polyketomycin-related

products

in

S.

diastatochromogenes Tü6028 [11]. DutMT2 shares 95% similarity and 93% identity
with PokMT3. BLAST analysis also revealed that DutMT2 is homology to TcmN (51%
identity and 65% similarity), a bifunctional protein that can catalyze the regiospecific
cyclization and O-methylation of the tetracenomycin [12]. However, DutMT2 (350 aa)
is much shorter than TcmN (494 aa), and lacks the N-terminal cyclization domain.
Thus, it is unlikely to participate in the cyclization process. The putative function of
DutMT2 is the 2-O-MT. However, given the fact that both inactivation of DutMT2 in
S. minoensis NRRL B-5482 and PokMT3 in S. diastatochromogenes Tü6028
completely disrupted the corresponding biosynthetic pathway, this type of MT may
also play an essential role in coordinating the collaborative actions of other
biosynthetic enzymes.

5.3.5 Inactivation of DutGT1 and DutGT2 and Characterization of Two New
Dutomycin Analogs.
Deoxysugars are frequently present in bioactive molecules such as erythromycin,
doxorubicin and pradimicin A. Some of these sugar moieties are found to be essential
in the biological activities. Thus, identification of enzymes responsible for
transferring these sugars is of interest. There are two putative GTs in the dut
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Fig. 22 HPLC analysis of the mutants of S. minoensis NRRL-B5482 at 460 nm. Trace
i: ΔDutMT1; trace ii: ΔDutGT2; trace iii: ΔDutGT1.

biosynthetic gene cluster, likely involved in introduction of the two sugar moieties to
the aglycone. In order to distinguish the roles of these two GTs and understand their
roles, the dutGT2 gene was disrupted using the same single crossover approach. The
correct ΔDutGT2 mutant was verified by PCR (Appendix E). LC-MS analysis of the
ethyl acetate of the culture of this mutant revealed that 4 was not produced, but a new
product 7 accumulated as the major metabolite at 8.2 min (trace ii, Fig. 23). ESI-MS
spectrum of 4 showed a [M-H]- ion peak at m/z 571.1, indicating that its molecular
weight is 572. This corresponds to the structure of the aglycone with D-amicetose,
which is the first sugar moiety in 4. To confirm the structure, 7 was isolated from 1 l
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of the culture. The purified compound was subjected to 1D and 2D NMR analysis. A
comparison of the NMR data of 7 and 4 revealed that the second sugar moiety and
attached C-4" side chain were missing in this new compound, confirming that its
structure

only

has

the

D-amicetose

moiety.

The

spin

system

of

H-1'/H2-2'/H2-3'/H-4'/H-5'/H3-6' of this sugar moiety was observed in the 1H-1H
COSY spectrum (Fig. 24). Accordingly, the structure of 7 can be established as shown
in Fig. 19 and was named as SW82. The proton and carbon signals were assigned
based on the 1D and 2D NMR spectra and a comparison with the data of 4. The
assigned signals of 7 are listed in Tables 7 and 8, respectively. The titer of 7 was
determined to be 34.8±0.2 mg/l. Identification of 7 indicated that the function of
DutGT2 is the GT responsible for transferring the second sugar (L-axenose) moiety.
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Fig. 23 Selected 1H-1H COSY and HMBC spectra for 6 and 7.

The dutGT1 gene was disrupted using the same single crossover approach as well.
The correct ΔDutGT1 mutant was verified by PCR. LC-MS analysis of the ethyl
acetate of the culture of this mutant revealed that 4 was not produced, but a major
product 8 at 7.0 min was produced (trace iii, Fig. 23). The ESI-MS spectrum of 8
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showed a [M-H]- ion peak at m/z 457.0 (Appendix E), suggesting that the molecular
weight of this compound is 458, which corresponds to the aglycone intermediate in
dutomycin biosynthesis (Fig.20B). The identity of 8 was confirmed by a comparison
of the methanolysis product of 4 (Appendix E). DutGT1 is thus confirmed to be
responsible for introducing the first sugar moiety to the aglycone.

5.3.6 Minimum inhibition concentration test for dutomycin and its novel derivatives.
In our initial screening for antibacterial microbial extracts, the ethyl acetate extract
of S. minoensis NRRL B-5482 was tested against three bacterial strains including
Gram-negative bacterium E. coli ATCC 25922 and the Gram-positive bacterial strains
S. aureus (SA) ATCC 25923 and methicillin-resistant S. aureus (MRSA) ATCC 33591.
This extract was active against SA and MRSA, with MIC values of 500 and 1000 µg/ml,
respectively. In contrast, it did not show any activity to E. coli (Table 9). After
purifying compounds 4-7 from the wild type or mutants, we texted these molecules
against the same panel of bacterial strains. 4 showed significant antibacterial activity
against the Gram-positive strains, but was not active against the Gram-negative strain
E. coli. This indicated that 4 specifically targets Gram-positive bacteria. The MIC
values of 4 for both SA and MRSA were determined to be 0.25 μg/ml, indicating that
this compound is a highly active antibacterial agent. Anthracyclines are ranked among
the most effective anticancer drugs ever developed [13]. The first anthracyclines
discovered were rhodomycin and cinerubicin [14]. Daunorubicin (trade name
Daunomycin) was later isolated from Streptomyces peucetius.[15] Anthracyclines can
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inhibit DNA and RNA synthesis and topoisomerase II enzyme to prevent the rapidly
growth of cells.[16-18] They were also found to generate free oxygen radicals to
damage the DNA, protein and cell membranes. [16] Hence, many anthracyclines,
such as daunorubicin, epirubicin, doxorubicin and aclacinomycin, are used in clinic as
cancer therapeutics. 4 was previously discovered as an antitumor compound [19] and
showed strong in vitro cytotoxicity against leukemia P388 cells. [19]

This is the first

time it was found to be a potent antibacterial agent. Its natural analog polyketomycin
from other actinomycetes has also shown similar antibacterial activity against
Gram-positive bacteria. This suggests that this family of anthracyclines represents
promising lead compounds for new antibiotics development.

The activity of 5-7 was also tested. However, this compound has no obvious
antibacterial activity and the MICs were 250 µg/ml, which is 1,000-fold higher than 4.
The MICs of 6 against SA and MRSA were determined to be 0.125 µg/ml, while
those of 7 were 250 µg/ml (Table 9). These antibacterial testing results of four
compounds revealed some important SAR information. The presence of the C-4" side
chain synthesized by the type I PKS DutG in 4 is essential, as removal of this side
chain led to almost complete loss of the antibacterial activity. The same phenomenon
was observed for 7, which lacks both the L-axenose moiety and the attached C-4"
polyketide chain, further confirming that the important role of this functional role. 6 is
a demethylated derivative of 4. Its MICs were only 50% of those of 4, indicating that
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removal of the 13-CH3 can significantly increase the antibacterial activity. The
activity of 8 was not tested as it lacks the sugar moieties and C-4" side chain, it is
expected that this compound has no antibacterial activity.
Table 9. MICs (µg/ml) of 4-7 against three bacterial strains.

Crude extract
4
5
6
7

E. coli
--->250
>250
>250
>250

SA
500
0.25
250
0.125
250

MRSA
1000
0.25
250
0.125
250

5.4 Conclusion
In this study, dutomycin and its precursor POK-MD1 was isolated from
S.minoensis NRRL B-5482 and structurally characterized. The dutomycin
biosynthetic gene cluster was identified through genome sequencing and gene
disruption, and the genes were annotated with putative functions based on sequence
homology. Three new dutomycin analogs were generated through gene disruption.
Antibacterial studies on these molecules revealed that the C-4" side chain plays an
essential role in the biological activity on dutomycin. Removal the CH3-13
significantly improved the antibacterial activity, suggesting that it is possible to create
new dutomycin analogs through engineered biosynthesis and the antibacterial activity
may be further optimized by additional structural modifications to yield novel
antibiotics to combat Gram-positive pathogens including those developed with
drug-resistance.
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CHAPTER 6 SUMMARY AND ENGINEERING VALUE

6.1 Summary
In summary, this research has engineered polyketide biosynthetic pathways via
two different approaches to make valuable bioactive molecules. Through heterologous
expression, we built a very flexible yet efficient biosynthetic platform for the
production of various plant natural products in E. coli. Enzymes from different
sources were used as biosynthetic bricks that can be rationally recombined as legos
for desired products. A variety of bioactive molecules naturally from plants have been
produced in engineered E. coli strains within 2-3 days. Manipulation of these
constructed pathways by removal or addition of biosynthetic enzymes led to novel
“unnatural” molecules. A visible reporter assay was designed to facilitate the
screening of efficient PALs, which are involved in the first biosynthetic steps of many
plant phenylpropanoids. In addition to construction of artificial pathways in
heterologous hosts, natural product biosynthetic pathways can also be modified
through gene disruption in the original producing strain to yield new bioactive
compounds. The biosynthetic gene cluster of dutomycin, a natural antibacterial and
anticancer molecule, was discovered through genome sequencing and targeted gene
disruption. Several enzymes in this pathway were functionally characterized.
Moreover, a new demethylated analog of dutomycin was generated, which showed a
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much

higher

antibacterial

activity

against

Staphylococcus

aureus

and

methicillin-resistant Staphylococcus aureus than the original natural product.

6.2 Engineering value

6.2.1 Engineered production of hydroxycinnamic acids and stilbenoids in E. coli
Hydroxycinnamic acids (HCAs) are important phytochemicals possessing
significant biological properties such as management of oxidative stress-related
diseases. Stilbenoids, containing a C6-C2-C6 core structure, are a class of plant
secondary metabolites often involved in injury therapy when the plant is threatened by
bacteria or fungi. These molecules have shown a variety of biological properties, such
as antioxidant, antibacterial, antifungal, anticancer, anti-inflammatory and anti-aging
activities. In Chapter 2, we produced resveratrol from L-tyrosine in a yield of 114 mg/l
by engineering an artificial biosynthetic pathway into E. coli and optimizing the
fermentation conditions. This yield is much higher than those previously reported.
Furthermore, piceatannol is a hydroxylated derivative with better biological activities,
but the application of this compound is limited by low yield in plants, which explains
the high price of this compound. In Chapter 2, we made it possible to produce
piceatannol in the E. coli system with the platform we established. The engineered E.
coli strain that harbors C3H can efficiently convert the relatively inexpensive
compound resveratrol ($1.05/mg) to piceatannol ($40/mg) for a yield of 65 mg/l in 2
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days. This research thus provides a new method for large scale production of
piceatannol.

6.2.2 Engineered biosynthesis of curcuminoids and two “unnatural” molecules in E.
coli.
Curcuminoids are used as food spice (curry) and food coloring agent (E100). In
addition, they are the major bioactive components in turmeric that have been used in
Asian traditional medicine for centuries. Curcuminoids are well-known for their
anti-tumor, anti-oxidant, anti-inflammatory, anti-allergic, and hepatoprotective
activities. In Chapter 3, we modified the platform established in Chapter 2 with more
genes from plants and successfully produced three different natural curcuminoids.
While curcuminoids are present as a mixture in nature, this method allowed the
production of a single curcuminoid in E. coli. That simplifies the downstream
processing and purification of the three different curcuminoids that have similar
physical and chemical properties. Also in Chapter 3, two novel unnatural compounds
were generated by E. coli via genetic modification of the pathways. This
demonstrated a highly efficient combinatorial biosynthesis approach to creating
various plant phenylpropanoids in E. coli.

6.2.3 Design and application of an in vivo reporter assay for phenylalanine
ammonia-lyase
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Phenylalanine ammonia-lyase (PAL) is an important enzyme that links primary
metabolism to secondary metabolism. Its efficiency is often a critical factor that
affects the overall flux of a related metabolic pathway, the titer of the final products,
and the efficacy of PAL-based therapies. In Chapter 4, a novel and efficient visible
reporter assay for screening of PAL efficiency in E. coli was established based on the
curcuminoid polyketide biosynthetic pathway. Taking advantage of the yellow color
of the product, a microplate-based assay was designed to measure the titer of
dicinnamoylmethane, which was validated by HPLC analysis. The different titers of
the product reflect the overall performance (expression level and enzymatic activity)
of the individual PALs in E. coli. This provides a convenient way to screen efficient
PALs for various pathways including plant phenylpropanoid biosynthetic pathways
studied in this dissertation.

6.2.4 Biosynthesis and antibacterial activity of dutomycin and analogs
In this study, dutomycin and its precursor POK-MD1 were isolated from S.
minoensis NRRL B-5482 and structurally characterized. The dutomycin biosynthetic
gene cluster was identified through genome sequencing and gene disruption. The
genes were annotated with putative functions based on sequence homology. Three
new dutomycin analogs were generated through gene disruption. Antibacterial studies
on these molecules revealed that the C-4" side chain plays an essential role in the
biological activity on dutomycin. Removal of the CH3-13 significantly improved the
antibacterial activity, suggesting that it is possible to create new dutomycin analogs
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through engineered biosynthesis. Antibacterial activity may be further optimized by
additional structural modifications to yield novel antibiotics for combating
Gram-positive pathogens, including those developed with drug-resistance. All these
studies open the door for further engineering, bioactivity screening, improvement, and
clinical use of the novel antibiotic, dutomycin.
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APPENDIX B
Resveratrol: 1H NMR (DMSO-d6 ) δ 9.53 (1H, s), 9.18 (2H, s), 7.39 (2H, d, J = 8.6),
6.94 (1H, d, J = 16.5), 6.80 (1H, d, J = 16.5), 6.75 (2H, d, J = 8.6), 6.38 (2H, d, J =
1.3), 6.12 (1H, d, J = 1.3).

Fig.B1. ESI-MS analyses of hydroxycinnamic acids production. a. ESI-MS (-)
spectrum of p-coumaric acid production from tyrosine; b. ESI-MS (-) spectrum of
caffeic acid production from tyrosine; c. ESI-MS (-) spectrum of ferulic acid
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production from tyrosine; d. ESI-MS (-) spectrum of cinnamic acid production from
phenylalanine.

Fig.B2. LC-MS analyses of resveratrol production. a. ESI-MS (+) spectrum of
resveratrol production from tyrosine; b. ESI-MS (-) spectrum of resveratrol
production from tyrosine; c. UV spectrum of resveratrol production from tyrosine.
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Fig. B3. LC-MS analyses of natural stilbenoids production. a. ESI-MS (-) spectrum of
piceatannol production from tyrosine; b. UV spectrum of piceatannol production from
tyrosine; c. ESI-MS (-) spectrum of pinosylvin production from phenylalanine; d. UV
spectrum of pinosylvin production from phenylalanine.
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APPENDIX C
Curcumin1H NMR (acetone-d6) δ 7.60 (2H, d, J = 15.4), 7.33 (2H, d, J = 2.0), 7.17
(2H, dd, J = 8.2, 2.0), 6.88 (2H, d, J = 8.2), 6.70 (2H, d, J = 16.5), 5.97 (1H, s).

2-Chloro- resveratrol: 1H NMR (CD3OD) δ 7.38 (2H, d, J = 8.6), 7.27 (1H, d, J =
16.1), 6.95 (1H, d, J = 16.1), 6.79 (2H, d, J = 8.6), 6.67 (1H, d, J = 2.8), 6.33 (1H, d, J
= 2.8).

Dicafferolmethane: 1H NMR (CD3OD) δ7.50 (2H, d, J = 15.7), 7.07 (2H, brs),
7.00(2H, d, J = 7.5), 6.79 (2H, d, J = 7.5), 6.54 (2H, d, J = 15.7), 5.94 (1H, s).
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APPENDIX D

Table D1. 1H (300 MHz) and 13C (75 MHz) NMR data for 2 (acetone-d6, δ in
ppm, J in Hz)
1

Position

H

13

C

1

6.17 (1H, s)

103.3

2

---

182.9

3

6.90 (1H, d, J = 16.0)

129.1

4

7.70 (1H, d, J = 15.9)

136.1

5

---

123.9

6

---

163.3

7

7.22 (1H, dd, J = 2.5, 8.2)

116.8

8

7.75–7.78 (1H, m)

117.1

9

7.28 (1H, t, J = 7.7)

125.8

10

7.81–7.83 (1H, m)

131.9

2'

---

184.9

3'

6.94 (1H, d, J = 16.0)

129.2

4'

7.77 (1H, d, J = 16.1)

140.7

5'

---

124.2

6'

7.70 (1H, dd, J = 2.5, 7.7)

130.6

7'

7.41–7.44 (1H, m)

130.7

8'

7.37–7.41(1H, m)

129.9

9'

7.41–7.44 (1H, m)

130.7

10'

7.70 (1H, dd, J = 2.5, 7.7)

130.6
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Table D2.

Time course analysis of the production of 1 by different PALs through

UV-Vis microplate reader and HPLC analyses. The yields were calculated
from three independent experiments and are presented as mean ± SD (g/l).
Method

Time

PAL1

PAL3

PAL4

12 h

0.087±0.007

0.011±0.001

0.014±0.001

24 h

0.201±0.005

0.032±0.001

0.036±0.004

36 h

0.233±0.005

0.038±0.006

0.044±0.004

48 h

0.271±0.018

0.047±0.003

0.082±0.008

60 h

0.343±0.012

0.073±0.019

0.092±0.005

72 h

0.367±0.004

0.081±0.006

0.118±0.012

12 h

0.053±0.003

0.012±0.001

0.012±0.001

24 h

0.159±0.005

0.022±0.001

0.046±0.004

36 h

0.212±0.004

0.042±0.007

0.049±0.004

48 h

0.248±0.009

0.053±0.003

0.078±0.008

60 h

0.342±0.003

0.072±0.004

0.082±0.002

72 h

0.367±0.011

0.080±0.008

0.105±0.011

HPLC

UV-Vis
Microplate
reader
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Fig. E1. Typical UV absorptions of anthracycline antibiotics.
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Fig E3 Time course of Streptomyces minoensis NRRL-B5482 production.
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Table E1. Primers used in this study.*
Primer

Sequence

Type II KS-F

5’-TSGCSTGCTTCGAYGCSATC-3’

Type II KS-R

5’-TGGAANCCGCCGAABCCGCT-3’

DutMT1-F

5’-AAAAGCTTCCTGCGCGACATGGTCCTGT-3’

DutMT1-R

5'-AATCTAGACGACCAGGTTCTCGATCACG-3'

DutMT2-F

5'-AAAAGCTTGCTCTACCGGATGCTGCGCT-3'

DutMT2-R

5’-AATCTAGACTTCAGGACGTACGCGTCGC-3’

DutGT2-F

5’-AAAAGCTTACGGCATCCTGGACGAGCAT-3’

DutGT2-R

5’-AATCTAGATTCGGCTGGGCGACGATCAA-3’

DutGT1-F

5’- AAAAGCTTGATCCGCGCGCTGTA -3’

DutGT1-R

5’- AATCTAGAATCTCTGTGCAGATCGGTGA -3’

DutKS-Check1

5’-GTCTCCACGGGCTGTACCTC-3’

DutKS-Check2

5’-ATCAGCCGGCTGGGCAGATG-3’

DutMT1-Check1

5’- ATGACAGCTCCCGCTCTCGAA -3’

DutMT1-Check2

5’- ATTTATTGGCGTCATCAGGTTGT -3’

DutMT2-Check1

5’- AGCCTCCGAAGAGGCTCGG -3’

DutMT2-Check2

5’- TTCTGCCAGATCGAGCGCCT -3’

DutGT2-Check1

5’-AGATCAAGCACAGTCCGGA-3’

DutGT2-Check2

5’-AAGCGACTCTGGAAGAGG-3’

DutGT1-Check1

5’-ATGGTCGACGAGTACGT-3’

DutGT1-Check2

5’- TGACGATGTCGATGGCCAA-3’

M13-47

5’-CGCCAGGGTTTTCCCAGTCACGAC-3’

RM-V

5’-GAGCGGATAACAATTTCACACAGG-3’
* Restriction sites are shown in bold.
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Fig. E8 The identity of 8 was confirmed by a comparison of the methanolysis product
of 4.
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Engineering design components in Chapters 2 and 3: Biosynthetic enzymes from
different sources were used to design artificial metabolic pathways to produce various
molecules. A libray of biosynthetic bricks was constructed and various biosynthetic
pathways were assembled in E. coli using these biosynthetic bricks to generate four
phenylpropanoid acids (cinnamic acid, p-coumaric acid, caffeic acid, and ferulic acid),
three bioactive natural stilbenoids (resveratrol, piceatannol and pinosylvin), and three
natural curcuminoids (curcumin, bisdemethoxycurcumin and dicinnamoylmethane)
The yields were improved by optimizing the substrate concentrations.

Engineering design components in Chapter 4: Taking advantage of the yellow
color of dicinnamoylmethane, a novel and visible microplate-based assay was
designed for screening highly efficient PALs. This method requires remarkably
smaller volumes, lower costs and shorter time compared to traditional analytic
methods. This assay can be widely used in the industry or academia to search novel
PALs for production improvement or therapeutics development.

Engineering design components in Chapter 5: The dutomycin biosynthetic gene
cluster was discovered by genome sequencing and confirmed by gene disruption.
Three new dutomycin analogs were generated by manipulating the pathway. This
work thus provides a biosynthetic approach to creating new antibacterial agents.
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